A BILL 
To clarify the regulatory framework with respect to certain 
nonprescription drugs that are marketed without an ap-
proved drug application, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE; TABLE OF CONTENTS. 
3
(a) SHORT TITLE.—This Act may be cited as the 
4
‘‘Over-the-Counter Monograph Safety, Innovation, and 
5
Reform Act of 2019’’. 
6
(b) TABLE OF CONTENTS.—The table of contents for 
7
this Act is as follows: 
8
Sec. 1. Short title; table of contents. 
04:32 Jun 29, 2019
H3443
2 
•HR 3443 IH
TITLE I—OTC DRUG REVIEW 
Sec. 1001. Regulation of certain nonprescription drugs that are marketed with-
out an approved drug application. 
Sec. 1002. Misbranding. 
Sec. 1003. Drugs excluded from the over-the-counter drug review. 
Sec. 1004. Treatment of Sunscreen Innovation Act. 
Sec. 1005. Annual update to Congress on appropriate pediatric indication for 
certain OTC cough and cold drugs. 
Sec. 1006. Technical corrections. 
TITLE II—USER FEES 
Sec. 2001. Short title; finding. 
Sec. 2002. Fees relating to over-the-counter drugs. 
TITLE I—OTC DRUG REVIEW 
1
SEC. 1001. REGULATION OF CERTAIN NONPRESCRIPTION 
2
DRUGS THAT ARE MARKETED WITHOUT AN 
3
APPROVED DRUG APPLICATION. 
4
(a) IN GENERAL.—Chapter V of the Federal Food, 
5
Drug, and Cosmetic Act is amended by inserting after sec-
6
tion 505F of such Act (21 U.S.C. 355g) the following: 
7
‘‘SEC. 505G. REGULATION OF CERTAIN NONPRESCRIPTION 
8
DRUGS THAT ARE MARKETED WITHOUT AN 
9
APPROVED DRUG APPLICATION. 
10
‘‘(a) NONPRESCRIPTION DRUGS MARKETED WITH-
11
OUT
AN
APPROVED
APPLICATION.—Nonprescription 
12
drugs marketed without an approved drug application 
13
under section 505, as of the date of the enactment of this 
14
section, shall be treated in accordance with this sub-
15
section. 
16
‘‘(1) DRUGS SUBJECT TO A FINAL MONOGRAPH; 
17
CATEGORY
I
DRUGS
SUBJECT
TO
A
TENTATIVE 
18
FINAL MONOGRAPH.—A drug is deemed to be gen-
19
04:32 Jun 29, 2019
H3443
3 
•HR 3443 IH
erally recognized as safe and effective under section 
1
201(p)(1), not a new drug under section 201(p), and 
2
not subject to section 503(b)(1), if— 
3
‘‘(A) the drug is— 
4
‘‘(i) in conformity with the require-
5
ments for nonprescription use of a final 
6
monograph issued under part 330 of title 
7
21, Code of Federal Regulations (except as 
8
provided in paragraph (2)), the general re-
9
quirements for nonprescription drugs, and 
10
conditions or requirements under sub-
11
sections (b), (c), and (k); and 
12
‘‘(ii) except as permitted by an order 
13
issued under subsection (b) or, in the case 
14
of a minor change in the drug, in con-
15
formity with an order issued under sub-
16
section (c), in a dosage form that, imme-
17
diately prior to the date of the enactment 
18
of this section, has been used to a material 
19
extent and for a material time under sec-
20
tion 201(p)(2); or 
21
‘‘(B) the drug is— 
22
‘‘(i) classified in category I for safety 
23
and effectiveness under a tentative final 
24
monograph that is the most recently appli-
25
04:32 Jun 29, 2019
H3443
4 
•HR 3443 IH
cable proposal or determination issued 
1
under part 330 of title 21, Code of Federal 
2
Regulations; 
3
‘‘(ii) in conformity with the proposed 
4
requirements for nonprescription use of 
5
such tentative final monograph, any appli-
6
cable subsequent determination by the Sec-
7
retary, the general requirements for non-
8
prescription drugs, and conditions or re-
9
quirements under subsections (b), (c), and 
10
(k); and 
11
‘‘(iii) except as permitted by an order 
12
issued under subsection (b) or, in the case 
13
of a minor change in the drug, in con-
14
formity with an order issued under sub-
15
section (c), in a dosage form that, imme-
16
diately prior to the date of the enactment 
17
of this section, has been used to a material 
18
extent and for a material time under sec-
19
tion 201(p)(2). 
20
‘‘(2) TREATMENT
OF
SUNSCREEN
DRUGS.— 
21
With respect to sunscreen drugs subject to this sec-
22
tion, the applicable requirements in terms of con-
23
formity with a final monograph, for purposes of 
24
paragraph (1)(A)(i), shall be the requirements speci-
25
04:32 Jun 29, 2019
H3443
5 
•HR 3443 IH
fied in part 352 of title 21, Code of Federal Regula-
1
tions, as published on May 21, 1999, beginning on 
2
page 27687 of volume 64 of the Federal Register, 
3
except that the applicable requirements governing ef-
4
fectiveness and labeling shall be those specified in 
5
section 201.327 of title 21, Code of Federal Regula-
6
tions. 
7
‘‘(3) CATEGORY III DRUGS SUBJECT TO A TEN-
8
TATIVE
FINAL
MONOGRAPH; CATEGORY
I
DRUGS 
9
SUBJECT TO PROPOSED MONOGRAPH OR ADVANCE 
10
NOTICE OF PROPOSED RULEMAKING.—A drug that 
11
is not described in paragraph (1), (2), or (4) is not 
12
required to be the subject of an application approved 
13
under section 505, and is not subject to section 
14
503(b)(1), if— 
15
‘‘(A) the drug is— 
16
‘‘(i) classified in category III for safe-
17
ty or effectiveness in the preamble of a 
18
proposed rule establishing a tentative final 
19
monograph that is the most recently appli-
20
cable proposal or determination for such 
21
drug issued under part 330 of title 21, 
22
Code of Federal Regulations; 
23
‘‘(ii) in conformity with— 
24
04:32 Jun 29, 2019
H3443
6 
•HR 3443 IH
‘‘(I) the conditions of use, includ-
1
ing indication and dosage strength, if 
2
any, described for such category III 
3
drug in such preamble or in an appli-
4
cable subsequent proposed rule; 
5
‘‘(II) the proposed requirements 
6
for drugs classified in such tentative 
7
final monograph in category I in the 
8
most recently proposed rule estab-
9
lishing requirements related to such 
10
tentative final monograph and in any 
11
final rule establishing requirements 
12
that are applicable to the drug; and 
13
‘‘(III) the general requirements 
14
for nonprescription drugs and condi-
15
tions or requirements under sub-
16
section (b) or (k); and 
17
‘‘(iii) in a dosage form that, imme-
18
diately prior to the date of the enactment 
19
of this section, had been used to a material 
20
extent and for a material time under sec-
21
tion 201(p)(2); or 
22
‘‘(B) the drug is— 
23
‘‘(i) classified in category I for safety 
24
and effectiveness under a proposed mono-
25
04:32 Jun 29, 2019
H3443
7 
•HR 3443 IH
graph or advance notice of proposed rule-
1
making that is the most recently applicable 
2
proposal or determination for such drug 
3
issued under part 330 of title 21, Code of 
4
Federal Regulations; 
5
‘‘(ii) in conformity with the require-
6
ments for nonprescription use of such pro-
7
posed monograph or advance notice of pro-
8
posed rulemaking, any applicable subse-
9
quent determination by the Secretary, the 
10
general requirements for nonprescription 
11
drugs, and conditions or requirements 
12
under subsection (b) or (k); and 
13
‘‘(iii) in a dosage form that, imme-
14
diately prior to the date of the enactment 
15
of this section, has been used to a material 
16
extent and for a material time under sec-
17
tion 201(p)(2). 
18
‘‘(4) CATEGORY
II
DRUGS
DEEMED
NEW 
19
DRUGS.—A drug that is classified in category II for 
20
safety or effectiveness under a tentative final mono-
21
graph or that is subject to a determination to be not 
22
generally recognized as safe and effective in a pro-
23
posed rule that is the most recently applicable pro-
24
posal issued under part 330 of title 21, Code of Fed-
25
04:32 Jun 29, 2019
H3443
8 
•HR 3443 IH
eral Regulations, shall be deemed to be a new drug 
1
under section 201(p), misbranded under section 
2
502(ee), and subject to the requirement for an ap-
3
proved new drug application under section 505 be-
4
ginning on the day that is 180 calendar days after 
5
the date of the enactment of this section, unless, be-
6
fore such day, the Secretary determines that it is in 
7
the interest of public health to extend the period 
8
during which the drug may be marketed without 
9
such an approved new drug application. 
10
‘‘(5) 
DRUGS
NOT
GRASE
DEEMED
NEW 
11
DRUGS.—A drug that the Secretary has determined 
12
not to be generally recognized as safe and effective 
13
under section 201(p)(1) under a final determination 
14
issued under part 330 of title 21, Code of Federal 
15
Regulations, shall be deemed to be a new drug under 
16
section 201(p), misbranded under section 502(ee), 
17
and subject to the requirement for an approved new 
18
drug application under section 505. 
19
‘‘(6) OTHER DRUGS DEEMED NEW DRUGS.— 
20
Except as provided in subsection (m), a drug is 
21
deemed to be a new drug under section 201(p) and 
22
misbranded under section 502(ee) if the drug— 
23
‘‘(A) is not subject to section 503(b)(1); 
24
and 
25
04:32 Jun 29, 2019
H3443
9 
•HR 3443 IH
‘‘(B) is not described in paragraph (1), 
1
(2), (3), (4), or (5), or subsection (b)(1)(B). 
2
‘‘(b) ADMINISTRATIVE ORDERS.— 
3
‘‘(1) IN GENERAL.— 
4
‘‘(A) 
DETERMINATION.—The 
Secretary 
5
may, on the initiative of the Secretary or at the 
6
request of one or more requestors, issue an ad-
7
ministrative order determining whether there 
8
are conditions under which a specific drug, a 
9
class of drugs, or a combination of drugs, is de-
10
termined to be— 
11
‘‘(i) not subject to section 503(b)(1); 
12
and 
13
‘‘(ii) generally recognized as safe and 
14
effective under section 201(p)(1). 
15
‘‘(B) EFFECT.—A drug or combination of 
16
drugs shall be deemed to not require approval 
17
under section 505 if such drug or combination 
18
of drugs— 
19
‘‘(i) is determined by the Secretary to 
20
meet the conditions specified in clauses (i) 
21
and (ii) of subparagraph (A); 
22
‘‘(ii) is marketed in conformity with 
23
an administrative order under this sub-
24
section; 
25
04:32 Jun 29, 2019
H3443
10 
•HR 3443 IH
‘‘(iii) meets the general requirements 
1
for nonprescription drugs; and 
2
‘‘(iv) meets the requirements under 
3
subsections (c) and (k). 
4
‘‘(C) STANDARD.—The Secretary shall find 
5
that a drug is not generally recognized as safe 
6
and effective under section 201(p)(1) if— 
7
‘‘(i) the evidence shows that the drug 
8
is not generally recognized as safe and ef-
9
fective under section 201(p)(1); or 
10
‘‘(ii) the evidence is inadequate to 
11
show that the drug is generally recognized 
12
as 
safe 
and 
effective 
under 
section 
13
201(p)(1). 
14
‘‘(2) ADMINISTRATIVE
ORDERS
INITIATED
BY 
15
THE SECRETARY.— 
16
‘‘(A) IN GENERAL.—In issuing an adminis-
17
trative order under paragraph (1) upon the 
18
Secretary’s initiative, the Secretary shall— 
19
‘‘(i) make reasonable efforts to notify 
20
informally, not later than 2 business days 
21
before the issuance of the proposed order, 
22
the sponsors of drugs who have a listing in 
23
effect under section 510(j) for the drugs or 
24
04:32 Jun 29, 2019
H3443
11 
•HR 3443 IH
combination of drugs that will be subject 
1
to the administrative order; 
2
‘‘(ii) after any such reasonable efforts 
3
of notification— 
4
‘‘(I) issue a proposed administra-
5
tive order by publishing it on the 
6
website of the Food and Drug Admin-
7
istration and include in such order the 
8
reasons for the issuance of such order; 
9
and 
10
‘‘(II) publish a notice of avail-
11
ability of such proposed order in the 
12
Federal Register; 
13
‘‘(iii) except as provided in subpara-
14
graph (B), provide for a public comment 
15
period with respect to such proposed order 
16
of not less than 45 calendar days; and 
17
‘‘(iv) if, after completion of the pro-
18
ceedings specified in clauses (i) through 
19
(iii), the Secretary determines that it is ap-
20
propriate to issue a final administrative 
21
order— 
22
‘‘(I) issue the final administrative 
23
order, together with a detailed state-
24
ment of reasons, which order shall not 
25
04:32 Jun 29, 2019
H3443
12 
•HR 3443 IH
take effect until the time for request-
1
ing judicial review under paragraph 
2
(3)(D)(ii) has expired; 
3
‘‘(II) publish a notice of such 
4
final administrative order in the Fed-
5
eral Register; 
6
‘‘(III) afford requestors of drugs 
7
that will be subject to such order the 
8
opportunity for formal dispute resolu-
9
tion up to the level of the Director of 
10
the Center for Drug Evaluation and 
11
Research, which initially must be re-
12
quested within 45 calendar days of 
13
the issuance of the order, and, for 
14
subsequent levels of appeal, within 30 
15
calendar days of the prior decision; 
16
and 
17
‘‘(IV) except with respect to 
18
drugs described in paragraph (3)(B), 
19
upon completion of the formal dispute 
20
resolution procedure, inform the per-
21
sons which sought such dispute reso-
22
lution of their right to request a hear-
23
ing. 
24
04:32 Jun 29, 2019
H3443
13 
•HR 3443 IH
‘‘(B) EXCEPTIONS.—When issuing an ad-
1
ministrative order under paragraph (1) on the 
2
Secretary’s initiative proposing to determine 
3
that a drug described in subsection (a)(3) is not 
4
generally recognized as safe and effective under 
5
section 201(p)(1), the Secretary shall follow the 
6
procedures in subparagraph (A), except that— 
7
‘‘(i) the proposed order shall include 
8
notice of— 
9
‘‘(I) the general categories of 
10
data the Secretary has determined 
11
necessary to establish that the drug is 
12
generally recognized as safe and effec-
13
tive under section 201(p)(1); and 
14
‘‘(II) the format for submissions 
15
by interested persons; 
16
‘‘(ii) the Secretary shall provide for a 
17
public comment period of no less than 180 
18
calendar days with respect to such pro-
19
posed order, except when the Secretary de-
20
termines, for good cause, that a shorter pe-
21
riod is in the interest of public health; and 
22
‘‘(iii) any person who submits data in 
23
such comment period shall include a cer-
24
tification that the person has submitted all 
25
04:32 Jun 29, 2019
H3443
14 
•HR 3443 IH
evidence created, obtained, or received by 
1
that person that is both within the cat-
2
egories of data identified in the proposed 
3
order and relevant to a determination as to 
4
whether the drug is generally recognized as 
5
safe and effective under section 201(p)(1). 
6
‘‘(3) HEARINGS; JUDICIAL REVIEW.— 
7
‘‘(A) IN
GENERAL.—Only a person who 
8
participated in each stage of formal dispute res-
9
olution under subclause (III) of paragraph 
10
(2)(A)(iv) of an administrative order with re-
11
spect to a drug may request a hearing con-
12
cerning a final administrative order issued 
13
under such paragraph with respect to such 
14
drug. If a hearing is sought, such person must 
15
submit a request for a hearing, which shall be 
16
based solely on information in the administra-
17
tive record, to the Secretary not later than 30 
18
calendar days after receiving notice of the final 
19
decision of the formal dispute resolution proce-
20
dure. 
21
‘‘(B) NO
HEARING
REQUIRED
WITH
RE-
22
SPECT
TO
ORDERS
RELATING
TO
CERTAIN 
23
DRUGS.— 
24
04:32 Jun 29, 2019
H3443
15 
•HR 3443 IH
‘‘(i) IN
GENERAL.—The Secretary 
1
shall not be required to provide notice and 
2
an opportunity for a hearing pursuant to 
3
paragraph (2)(A)(iv) if the final adminis-
4
trative order involved relates to a drug— 
5
‘‘(I) that is described in sub-
6
section (a)(3)(A); and 
7
‘‘(II) with respect to which no 
8
human or non-human data studies rel-
9
evant to the safety or effectiveness of 
10
such drug have been submitted to the 
11
administrative 
record 
since 
the 
12
issuance of the most recent tentative 
13
final monograph relating to such 
14
drug. 
15
‘‘(ii) HUMAN
DATA
STUDIES
AND 
16
NON-HUMAN DATA DEFINED.—In this sub-
17
paragraph: 
18
‘‘(I) The term ‘human data stud-
19
ies’ means clinical trials of safety or 
20
effectiveness (including actual use 
21
studies), pharmacokinetics studies, or 
22
bioavailability studies. 
23
‘‘(II) The term ‘non-human data’ 
24
means data from testing other than 
25
04:32 Jun 29, 2019
H3443
16 
•HR 3443 IH
with human subjects which provides 
1
information concerning safety or ef-
2
fectiveness. 
3
‘‘(C) HEARING PROCEDURES.— 
4
‘‘(i) DENIAL OF REQUEST FOR HEAR-
5
ING.—If the Secretary determines that in-
6
formation submitted in a request for a 
7
hearing under subparagraph (A) with re-
8
spect to a final administrative order issued 
9
under paragraph (2)(A)(iv) does not iden-
10
tify the existence of a genuine and sub-
11
stantial question of material fact, the Sec-
12
retary may deny such request. In making 
13
such a determination, the Secretary may 
14
consider only information and data that 
15
are based on relevant and reliable scientific 
16
principles and methodologies. 
17
‘‘(ii) SINGLE HEARING FOR MULTIPLE 
18
RELATED
REQUESTS.—If more than one 
19
request for a hearing is submitted with re-
20
spect to the same administrative order 
21
under subparagraph (A), the Secretary 
22
may direct that a single hearing be con-
23
ducted in which all persons whose hearing 
24
requests were granted may participate. 
25
04:32 Jun 29, 2019
H3443
17 
•HR 3443 IH
‘‘(iii) PRESIDING OFFICER.—The pre-
1
siding officer of a hearing requested under 
2
subparagraph (A) shall— 
3
‘‘(I) be designated by the Sec-
4
retary; 
5
‘‘(II) not be an employee of the 
6
Center for Drug Evaluation and Re-
7
search; and 
8
‘‘(III) not have been previously 
9
involved in the development of the ad-
10
ministrative order involved or pro-
11
ceedings relating to that administra-
12
tive order. 
13
‘‘(iv) RIGHTS OF PARTIES TO HEAR-
14
ING.—The parties to a hearing requested 
15
under subparagraph (A) shall have the 
16
right to present testimony, including testi-
17
mony of expert witnesses, and to cross-ex-
18
amine witnesses presented by other parties. 
19
Where appropriate, the presiding officer 
20
may require that cross-examination by par-
21
ties representing substantially the same in-
22
terests be consolidated to promote effi-
23
ciency and avoid duplication. 
24
‘‘(v) FINAL DECISION.— 
25
04:32 Jun 29, 2019
H3443
18 
•HR 3443 IH
‘‘(I) At the conclusion of a hear-
1
ing requested under subparagraph 
2
(A), the presiding officer of the hear-
3
ing shall issue a decision containing 
4
findings of fact and conclusions of 
5
law. The decision of the presiding offi-
6
cer shall be final. 
7
‘‘(II) The final decision may not 
8
take effect until the period under sub-
9
paragraph (D)(ii) for submitting a re-
10
quest for judicial review of such deci-
11
sion expires. 
12
‘‘(D) JUDICIAL REVIEW OF FINAL ADMIN-
13
ISTRATIVE ORDER.— 
14
‘‘(i) IN
GENERAL.—The procedures 
15
described in section 505(h) shall apply 
16
with respect to judicial review of final ad-
17
ministrative orders issued under this sub-
18
section in the same manner and to the 
19
same extent as such section applies to an 
20
order described in such section except that 
21
the judicial review shall be taken by filing 
22
in an appropriate district court of the 
23
United States in lieu of the appellate 
24
courts specified in such section. 
25
04:32 Jun 29, 2019
H3443
19 
•HR 3443 IH
‘‘(ii) PERIOD TO SUBMIT A REQUEST 
1
FOR JUDICIAL REVIEW.—A person eligible 
2
to request a hearing under this paragraph 
3
and seeking judicial review of a final ad-
4
ministrative order issued under this sub-
5
section shall file such request for judicial 
6
review not later than 60 calendar days 
7
after the latest of— 
8
‘‘(I) the date on which notice of 
9
such order is published; 
10
‘‘(II) the date on which a hearing 
11
with respect to such order is denied 
12
under subparagraph (B) or (C)(i); 
13
‘‘(III) the date on which a final 
14
decision is made following a hearing 
15
under subparagraph (C)(v); or 
16
‘‘(IV) if no hearing is requested, 
17
the date on which the time for re-
18
questing a hearing expires. 
19
‘‘(4) EXPEDITED PROCEDURE WITH RESPECT 
20
TO
ADMINISTRATIVE
ORDERS
INITIATED
BY
THE 
21
SECRETARY.— 
22
‘‘(A) IMMINENT HAZARD TO THE PUBLIC 
23
HEALTH.— 
24
04:32 Jun 29, 2019
H3443
20 
•HR 3443 IH
‘‘(i) IN GENERAL.—In the case of a 
1
determination by the Secretary that a 
2
drug, class of drugs, or combination of 
3
drugs subject to this section poses an im-
4
minent hazard to the public health, the 
5
Secretary, after first making reasonable ef-
6
forts to notify, not later than 48 hours be-
7
fore issuance of such order under this sub-
8
paragraph, sponsors who have a listing in 
9
effect under section 510(j) for such drug 
10
or combination of drugs— 
11
‘‘(I) may issue an interim final 
12
administrative order for such drug, 
13
class of drugs, or combination of 
14
drugs under paragraph (1), together 
15
with a detailed statement of the rea-
16
sons for such order; 
17
‘‘(II) shall publish in the Federal 
18
Register a notice of availability of any 
19
such order; and 
20
‘‘(III) shall provide for a public 
21
comment period of at least 45 cal-
22
endar days with respect to such in-
23
terim final order. 
24
04:32 Jun 29, 2019
H3443
21 
•HR 3443 IH
‘‘(ii) 
NONDELEGATION.—The 
Sec-
1
retary may not delegate the authority to 
2
issue an interim final administrative order 
3
under this subparagraph. 
4
‘‘(B) SAFETY LABELING CHANGES.— 
5
‘‘(i) IN GENERAL.—In the case of a 
6
determination by the Secretary that a 
7
change in the labeling of a drug, class of 
8
drugs, or combination of drugs subject to 
9
this section is reasonably expected to miti-
10
gate a significant or unreasonable risk of 
11
a serious adverse event associated with use 
12
of the drug, the Secretary may— 
13
‘‘(I) make reasonable efforts to 
14
notify informally, not later than 48 
15
hours before the issuance of the in-
16
terim final order, the sponsors of 
17
drugs who have a listing in effect 
18
under section 510(j) for such drug or 
19
combination of drugs; 
20
‘‘(II) after reasonable efforts of 
21
notification, issue an interim final ad-
22
ministrative order in accordance with 
23
paragraph (1) to require such change, 
24
04:32 Jun 29, 2019
H3443
22 
•HR 3443 IH
together with a detailed statement of 
1
the reasons for such order; 
2
‘‘(III) publish in the Federal 
3
Register a notice of availability of 
4
such order; and 
5
‘‘(IV) provide for a public com-
6
ment period of at least 45 calendar 
7
days with respect to such interim final 
8
order. 
9
‘‘(ii) CONTENT
OF
ORDER.—An in-
10
terim final order issued under this sub-
11
paragraph with respect to the labeling of a 
12
drug may provide for new warnings and 
13
other information required for safe use of 
14
the drug. 
15
‘‘(C) EFFECTIVE DATE.—An order under 
16
subparagraph (A) or (B) shall take effect on a 
17
date specified by the Secretary. 
18
‘‘(D) FINAL ORDER.—After the completion 
19
of the proceedings in subparagraph (A) or (B), 
20
the Secretary shall— 
21
‘‘(i) issue a final order in accordance 
22
with paragraph (1); 
23
04:32 Jun 29, 2019
H3443
23 
•HR 3443 IH
‘‘(ii) publish a notice of availability of 
1
such final administrative order in the Fed-
2
eral Register; and 
3
‘‘(iii) afford sponsors of such drugs 
4
that will be subject to such an order the 
5
opportunity for formal dispute resolution 
6
up to the level of the Director of the Cen-
7
ter for Drug Evaluation and Research, 
8
which must initially be within 45 calendar 
9
days of the issuance of the order, and for 
10
subsequent levels of appeal, within 30 cal-
11
endar days of the prior decision. 
12
‘‘(E) HEARINGS.—A sponsor of a drug 
13
subject to a final order issued under subpara-
14
graph (D) and that participated in each stage 
15
of formal dispute resolution under clause (iii) of 
16
such subparagraph may request a hearing on 
17
such order. The provisions of subparagraphs 
18
(A), (B), and (C) of paragraph (3), other than 
19
paragraph (3)(C)(v)(II), shall apply with re-
20
spect to a hearing on such order in the same 
21
manner and to the same extent as such provi-
22
sions apply with respect to a hearing on an ad-
23
ministrative order issued under paragraph 
24
(2)(A)(iv). 
25
04:32 Jun 29, 2019
H3443
24 
•HR 3443 IH
‘‘(F) TIMING.— 
1
‘‘(i) FINAL ORDER AND HEARING.— 
2
The Secretary shall— 
3
‘‘(I) not later than 6 months 
4
after the date on which the comment 
5
period closes under subparagraph (A) 
6
or (B), issue a final order in accord-
7
ance with paragraph (1); and 
8
‘‘(II) not later than 12 months 
9
after the date on which such final 
10
order is issued, complete any hearing 
11
under subparagraph (E). 
12
‘‘(ii) 
DISPUTE
RESOLUTION
RE-
13
QUEST.—The Secretary shall specify in an 
14
interim final order issued under subpara-
15
graph (A) or (B) such shorter periods for 
16
requesting dispute resolution under sub-
17
paragraph (D)(iii) as are necessary to 
18
meet the requirements of this subpara-
19
graph. 
20
‘‘(G) JUDICIAL
REVIEW.—A final order 
21
issued pursuant to subparagraph (F) shall be 
22
subject to judicial review in accordance with 
23
paragraph (3)(D). 
24
04:32 Jun 29, 2019
H3443
25 
•HR 3443 IH
‘‘(5) ADMINISTRATIVE
ORDER
INITIATED
AT 
1
THE REQUEST OF A REQUESTOR.— 
2
‘‘(A) IN GENERAL.—In issuing an adminis-
3
trative order under paragraph (1) at the re-
4
quest of a requestor with respect to certain 
5
drugs, classes of drugs, or combinations of 
6
drugs— 
7
‘‘(i) the Secretary shall, after receiv-
8
ing a request under this subparagraph, de-
9
termine whether the request is sufficiently 
10
complete and formatted to permit a sub-
11
stantive review; 
12
‘‘(ii) if the Secretary determines that 
13
the request is sufficiently complete and for-
14
matted to permit a substantive review, the 
15
Secretary shall— 
16
‘‘(I) file the request; and 
17
‘‘(II) initiate proceedings with re-
18
spect to issuing an administrative 
19
order in accordance with paragraphs 
20
(2) and (3); and 
21
‘‘(iii) except as provided in paragraph 
22
(6), if the Secretary determines that a re-
23
quest does not meet the requirements for 
24
filing or is not sufficiently complete and 
25
04:32 Jun 29, 2019
H3443
26 
•HR 3443 IH
formatted to permit a substantive review, 
1
the requestor may demand that the request 
2
be filed over protest, and the Secretary 
3
shall initiate proceedings to review the re-
4
quest in accordance with paragraph (2)(A). 
5
‘‘(B) 
REQUEST
TO
INITIATE
PRO-
6
CEEDINGS.— 
7
‘‘(i) IN GENERAL.—A requestor seek-
8
ing an administrative order under para-
9
graph (1) with respect to certain drugs, 
10
classes of drugs, or combinations of drugs, 
11
shall submit to the Secretary a request to 
12
initiate proceedings for such order in the 
13
form and manner as specified by the Sec-
14
retary. Such requestor may submit a re-
15
quest under this subparagraph for the 
16
issuance of an administrative order— 
17
‘‘(I) determining whether a drug 
18
is generally recognized as safe and ef-
19
fective under section 201(p)(1), ex-
20
empt from section 503(b)(1), and not 
21
required to be the subject of an ap-
22
proved application under section 505; 
23
or 
24
04:32 Jun 29, 2019
H3443
27 
•HR 3443 IH
‘‘(II) 
determining 
whether 
a 
1
change to a condition of use of a drug 
2
is generally recognized as safe and ef-
3
fective under section 201(p)(1), ex-
4
empt from section 503(b)(1), and not 
5
required to be the subject of an ap-
6
proved application under section 505, 
7
if, absent such a changed condition of 
8
use, such drug is— 
9
‘‘(aa) generally recognized 
10
as safe and effective under sec-
11
tion 201(p)(1) in accordance with 
12
subsection (a)(1), (a)(2), or an 
13
order under this subsection; or 
14
‘‘(bb) subject to subsection 
15
(a)(3), but only if such requestor 
16
initiates such request in conjunc-
17
tion with a request for the Sec-
18
retary to determine whether such 
19
drug is generally recognized as 
20
safe and effective under section 
21
201(p)(1), which is filed by the 
22
Secretary under subparagraph 
23
(A)(ii). 
24
04:32 Jun 29, 2019
H3443
28 
•HR 3443 IH
‘‘(ii) EXCEPTION.—The Secretary is 
1
not required to complete review of a re-
2
quest for a change described in clause 
3
(i)(II) if the Secretary determines that 
4
there is an inadequate basis to find the 
5
drug is generally recognized as safe and ef-
6
fective under section 201(p)(1) under para-
7
graph (1) and issues a final order an-
8
nouncing that determination. 
9
‘‘(iii) WITHDRAWAL.—The requestor 
10
may withdraw a request under this para-
11
graph, according to the procedures set 
12
forth pursuant to subsection (d)(2)(B). 
13
Notwithstanding any other provision of 
14
this section, if such request is withdrawn, 
15
the Secretary may cease proceedings under 
16
this subparagraph. 
17
‘‘(C) EXCLUSIVITY.— 
18
‘‘(i) IN GENERAL.—A final adminis-
19
trative order issued in response to a re-
20
quest under this section shall have the ef-
21
fect of authorizing solely the order re-
22
questor (or the licensees, assignees, or suc-
23
cessors in interest of such requestor with 
24
respect to the subject of such order), for a 
25
04:32 Jun 29, 2019
H3443
29 
•HR 3443 IH
period of 18 months following the effective 
1
date of such final order and beginning on 
2
the date the requestor may lawfully market 
3
such drugs pursuant to the order, to mar-
4
ket drugs— 
5
‘‘(I) incorporating changes de-
6
scribed in clause (ii); and 
7
‘‘(II) subject to the limitations 
8
under clause (iv). 
9
‘‘(ii) 
CHANGES
DESCRIBED.—A 
10
change described in this clause is a change 
11
subject to an order specified in clause (i), 
12
which— 
13
‘‘(I) provides for a drug to con-
14
tain an active ingredient (including 
15
any ester or salt of the active ingre-
16
dient) not previously incorporated in a 
17
drug described in clause (iii); or 
18
‘‘(II) provides for a change in the 
19
conditions of use of a drug, for which 
20
new human data studies conducted or 
21
sponsored by the requestor (or for 
22
which the requestor has an exclusive 
23
right of reference) were essential to 
24
the issuance of such order. 
25
04:32 Jun 29, 2019
H3443
30 
•HR 3443 IH
‘‘(iii) DRUGS DESCRIBED.—The drugs 
1
described in this clause are drugs— 
2
‘‘(I) 
specified 
in 
subsection 
3
(a)(1), (a)(2), or (a)(3); 
4
‘‘(II) subject to a final order 
5
issued under this section; 
6
‘‘(III) subject to a final sun-
7
screen order (as defined in section 
8
586(2)(A)); or 
9
‘‘(IV) described in subsection 
10
(m)(1), other than drugs subject to an 
11
active enforcement action under chap-
12
ter III of this Act. 
13
‘‘(iv) 
LIMITATIONS
ON
EXCLU-
14
SIVITY.— 
15
‘‘(I) IN GENERAL.—Only one 18- 
16
month period under this subpara-
17
graph shall be granted, under each 
18
order described in clause (i), with re-
19
spect to changes (to the drug subject 
20
to such order) which are either— 
21
‘‘(aa) changes described in 
22
clause (ii)(I), relating to active 
23
ingredients; or 
24
04:32 Jun 29, 2019
H3443
31 
•HR 3443 IH
‘‘(bb) changes described in 
1
clause (ii)(II), relating to condi-
2
tions of use. 
3
‘‘(II) 
NO
EXCLUSIVITY
AL-
4
LOWED.—No exclusivity shall apply to 
5
changes to a drug which are— 
6
‘‘(aa) the subject of a Tier 2 
7
OTC monograph order request 
8
(as defined in section 744L); 
9
‘‘(bb) safety-related changes, 
10
as defined by the Secretary, or 
11
any other changes the Secretary 
12
considers necessary to assure 
13
safe use; or 
14
‘‘(cc) changes related to 
15
methods of testing safety or effi-
16
cacy. 
17
‘‘(v) NEW HUMAN DATA STUDIES DE-
18
FINED.—In this subparagraph, the term 
19
‘new human data studies’ means clinical 
20
trials of safety or effectiveness (including 
21
actual use studies), pharmacokinetics stud-
22
ies, or bioavailability studies, the results of 
23
which— 
24
04:32 Jun 29, 2019
H3443
32 
•HR 3443 IH
‘‘(I) have not been relied on by 
1
the Secretary to support— 
2
‘‘(aa) a proposed or final de-
3
termination that a drug described 
4
in subclause (I), (II), or (III) of 
5
clause (iii) is generally recognized 
6
as safe and effective under sec-
7
tion 201(p)(1); or 
8
‘‘(bb) approval of a drug 
9
that was approved under section 
10
505; and 
11
‘‘(II) do not duplicate the results 
12
of another study that was relied on by 
13
the Secretary to support— 
14
‘‘(aa) a proposed or final de-
15
termination that a drug described 
16
in subclause (I), (II), or (III) of 
17
clause (iii) is generally recognized 
18
as safe and effective under sec-
19
tion 201(p)(1); or 
20
‘‘(bb) approval of a drug 
21
that was approved under section 
22
505. 
23
‘‘(6) INFORMATION
REGARDING
SAFE
NON-
24
PRESCRIPTION MARKETING AND USE AS CONDITION 
25
04:32 Jun 29, 2019
H3443
33 
•HR 3443 IH
FOR FILING A GENERALLY RECOGNIZED AS SAFE 
1
AND EFFECTIVE REQUEST.— 
2
‘‘(A) IN GENERAL.—In response to a re-
3
quest under this section that a drug described 
4
in subparagraph (B) be generally recognized as 
5
safe and effective, the Secretary— 
6
‘‘(i) may file such request, if the re-
7
quest includes information specified under 
8
subparagraph (C) with respect to safe non-
9
prescription marketing and use of such 
10
drug; or 
11
‘‘(ii) if the request fails to include in-
12
formation specified under subparagraph 
13
(C), shall refuse to file such request and 
14
require that nonprescription marketing of 
15
the drug be pursuant to a new drug appli-
16
cation as described in subparagraph (D). 
17
‘‘(B) DRUG
DESCRIBED.—A drug de-
18
scribed in this subparagraph is a nonprescrip-
19
tion drug which contains an active ingredient 
20
not previously incorporated in a drug— 
21
‘‘(i) specified in subsection (a)(1), 
22
(a)(2), or (a)(3); 
23
‘‘(ii) subject to a final order under 
24
this section; or 
25
04:32 Jun 29, 2019
H3443
34 
•HR 3443 IH
‘‘(iii) subject to a final sunscreen 
1
order (as defined in section 586(2)(A)). 
2
‘‘(C) 
INFORMATION
DEMONSTRATING 
3
PRIMA
FACIE
SAFE
NONPRESCRIPTION
MAR-
4
KETING
AND
USE.—Information specified in 
5
this subparagraph, with respect to a request de-
6
scribed in subparagraph (A)(i), is— 
7
‘‘(i) information sufficient for a prima 
8
facie demonstration that the drug subject 
9
to such request has a verifiable history of 
10
being marketed and safely used by con-
11
sumers in the United States as a non-
12
prescription drug under comparable condi-
13
tions of use; 
14
‘‘(ii) if the drug has not been pre-
15
viously marketed in the United States as a 
16
nonprescription drug, information suffi-
17
cient for a prima facie demonstration that 
18
the drug was marketed and safely used 
19
under comparable conditions of marketing 
20
and use in a country listed in section 
21
802(b)(1)(A) or designated by the Sec-
22
retary 
in 
accordance 
with 
section 
23
802(b)(1)(B)— 
24
04:32 Jun 29, 2019
H3443
35 
•HR 3443 IH
‘‘(I) for such period as needed to 
1
provide reasonable assurances con-
2
cerning the safe nonprescription use 
3
of the drug; and 
4
‘‘(II) during such time was sub-
5
ject to sufficient monitoring by a reg-
6
ulatory body considered acceptable by 
7
the Secretary for such monitoring 
8
purposes, including for adverse events 
9
associated with nonprescription use of 
10
the drug; or 
11
‘‘(iii) if the Secretary determines that 
12
information described in clause (i) or (ii) is 
13
not needed to provide a prima facie dem-
14
onstration that the drug can be safely mar-
15
keted and used as a nonprescription drug, 
16
such other information the Secretary deter-
17
mines is sufficient for such purposes. 
18
‘‘(D) MARKETING
PURSUANT
TO
NEW 
19
DRUG APPLICATION.—In the case of a request 
20
described in subparagraph (A)(ii), the drug 
21
subject to such request may be resubmitted for 
22
filing only if— 
23
‘‘(i) the drug is marketed as a non-
24
prescription drug, under conditions of use 
25
04:32 Jun 29, 2019
H3443
36 
•HR 3443 IH
comparable to the conditions specified in 
1
the request, for such period as the Sec-
2
retary determines appropriate (not to ex-
3
ceed 5 consecutive years) pursuant to an 
4
application approved under section 505; 
5
and 
6
‘‘(ii) during such period, 1,000,000 
7
retail packages of the drug, or an equiva-
8
lent quantity as determined by the Sec-
9
retary, were distributed for retail sale, as 
10
determined in such manner as the Sec-
11
retary finds appropriate. 
12
‘‘(E) RULE OF APPLICATION.—Except in 
13
the case of a request involving a drug described 
14
in section 586(9), as in effect on January 1, 
15
2017, if the Secretary refuses to file a request 
16
under this paragraph, the requestor may not 
17
file such request over protest under paragraph 
18
(5)(A)(iii). 
19
‘‘(7) PACKAGING.—An administrative order 
20
issued under paragraph (2), (4)(A), or (5) may in-
21
clude requirements for the packaging of a drug to 
22
encourage use in accordance with labeling. Such re-
23
quirements may include unit dose packaging, re-
24
quirements for products intended for use by pedi-
25
04:32 Jun 29, 2019
H3443
37 
•HR 3443 IH
atric populations, requirements to reduce risk of 
1
harm from unsupervised ingestion, and other appro-
2
priate requirements. This paragraph does not au-
3
thorize the Food and Drug Administration to re-
4
quire standards or testing procedures as described in 
5
part 1700 of title 16, Code of Federal Regulations. 
6
‘‘(8) FINAL
AND
TENTATIVE
FINAL
MONO-
7
GRAPHS FOR CATEGORY I DRUGS DEEMED FINAL 
8
ADMINISTRATIVE ORDERS.— 
9
‘‘(A) IN GENERAL.—A final monograph or 
10
tentative final monograph described in subpara-
11
graph (B) shall be deemed to be a final admin-
12
istrative order under this subsection and may 
13
be amended, revoked, or otherwise modified in 
14
accordance with the procedures of this sub-
15
section. 
16
‘‘(B) MONOGRAPHS DESCRIBED.—For pur-
17
poses of subparagraph (A), a final monograph 
18
or tentative final monograph is described in this 
19
subparagraph if it— 
20
‘‘(i) establishes conditions of use for a 
21
drug described in paragraph (1) or (2) of 
22
subsection (a); and 
23
‘‘(ii) represents the most recently pro-
24
mulgated version of such conditions, in-
25
04:32 Jun 29, 2019
H3443
38 
•HR 3443 IH
cluding as modified, in whole or in part, by 
1
any proposed or final rule. 
2
‘‘(C) DEEMED ORDERS INCLUDE HARMO-
3
NIZING
TECHNICAL
AMENDMENTS.—The 
4
deemed establishment of a final administrative 
5
order under subparagraph (A) shall be con-
6
strued to include any technical amendments to 
7
such order as the Secretary determines nec-
8
essary to ensure that such order is appro-
9
priately harmonized, in terms of terminology or 
10
cross-references, with the applicable provisions 
11
of this Act (and regulations thereunder) and 
12
any other orders issued under this section. 
13
‘‘(c) PROCEDURE FOR MINOR CHANGES.— 
14
‘‘(1) IN GENERAL.—Minor changes in the dos-
15
age form of a drug that is described in paragraph 
16
(1) or (2) of subsection (a) or the subject of an 
17
order issued under subsection (b) may be made by 
18
a requestor without the issuance of an order under 
19
subsection (b) if— 
20
‘‘(A) the requestor maintains such infor-
21
mation as is necessary to demonstrate that the 
22
change— 
23
‘‘(i) will not affect the safety or effec-
24
tiveness of the drug; and 
25
04:32 Jun 29, 2019
H3443
39 
•HR 3443 IH
‘‘(ii) will not materially affect the ex-
1
tent of absorption or other exposure to the 
2
active ingredient in comparison to a suit-
3
able reference product; and 
4
‘‘(B) the change is in conformity with the 
5
requirements of an applicable administrative 
6
order issued by the Secretary under paragraph 
7
(3). 
8
‘‘(2) ADDITIONAL INFORMATION.— 
9
‘‘(A) ACCESS
TO
RECORDS.—A sponsor 
10
shall submit records requested by the Secretary 
11
relating to such a minor change under section 
12
704(a)(4), within 15 business days of receiving 
13
such a request, or such longer period as the 
14
Secretary may provide. 
15
‘‘(B) INSUFFICIENT INFORMATION.—If the 
16
Secretary determines that the information con-
17
tained in such records is not sufficient to dem-
18
onstrate that the change does not affect the 
19
safety or effectiveness of the drug or materially 
20
affect the extent of absorption or other expo-
21
sure to the active ingredient, the Secretary— 
22
‘‘(i) may so inform the sponsor of the 
23
drug in writing; and 
24
04:32 Jun 29, 2019
H3443
40 
•HR 3443 IH
‘‘(ii) if the Secretary so informs the 
1
sponsor, shall provide the sponsor of the 
2
drug with a reasonable opportunity to pro-
3
vide additional information. 
4
‘‘(C) FAILURE TO SUBMIT SUFFICIENT IN-
5
FORMATION.—If the sponsor fails to provide 
6
such additional information within a time pre-
7
scribed by the Secretary, or if the Secretary de-
8
termines that such additional information does 
9
not demonstrate that the change does not— 
10
‘‘(i) affect the safety or effectiveness 
11
of the drug; or 
12
‘‘(ii) materially affect the extent of 
13
absorption or other exposure to the active 
14
ingredient in comparison to a suitable ref-
15
erence product, 
16
the drug as modified is a new drug under sec-
17
tion 201(p) and shall be deemed to be mis-
18
branded under section 502(ee). 
19
‘‘(3) DETERMINING WHETHER A CHANGE WILL 
20
AFFECT SAFETY OR EFFECTIVENESS.— 
21
‘‘(A) IN
GENERAL.—The Secretary shall 
22
issue one or more administrative orders speci-
23
fying requirements for determining whether a 
24
minor change made by a sponsor pursuant to 
25
04:32 Jun 29, 2019
H3443
41 
•HR 3443 IH
this subsection will affect the safety or effective-
1
ness of a drug or materially affect the extent of 
2
absorption or other exposure to an active ingre-
3
dient in the drug in comparison to a suitable 
4
reference product, together with guidance for 
5
applying those orders to specific dosage forms. 
6
‘‘(B) STANDARD PRACTICES.—The orders 
7
and guidance issued by the Secretary under 
8
subparagraph (A) shall take into account rel-
9
evant public standards and standard practices 
10
for evaluating the quality of drugs, and may 
11
take into account the special needs of popu-
12
lations, including children. 
13
‘‘(d) CONFIDENTIALITY
OF
INFORMATION
SUB-
14
MITTED TO THE SECRETARY.— 
15
‘‘(1) IN GENERAL.—Subject to paragraph (2), 
16
any information, including reports of testing con-
17
ducted on the drug or drugs involved, that is sub-
18
mitted by a requestor in connection with proceedings 
19
on an order under this section (including any minor 
20
change under subsection (c)) and is a trade secret 
21
or confidential information subject to section 
22
552(b)(4) of title 5, United States Code, or section 
23
1905 of title 18, United States Code, shall not be 
24
04:32 Jun 29, 2019
H3443
42 
•HR 3443 IH
disclosed to the public unless the requestor consents 
1
to that disclosure. 
2
‘‘(2) PUBLIC AVAILABILITY.— 
3
‘‘(A) IN GENERAL.—Except as provided in 
4
subparagraph (B), the Secretary shall— 
5
‘‘(i) make any information submitted 
6
by a requestor in support of a request 
7
under subsection (b)(5)(A) available to the 
8
public not later than the date on which the 
9
proposed order is issued; and 
10
‘‘(ii) make any information submitted 
11
by any other person with respect to an 
12
order requested (or initiated by the Sec-
13
retary) under subsection (b), available to 
14
the public upon such submission. 
15
‘‘(B) LIMITATIONS
ON
PUBLIC
AVAIL-
16
ABILITY.—Information described in subpara-
17
graph (A) shall not be made public if— 
18
‘‘(i) the information pertains to phar-
19
maceutical quality information, unless such 
20
information is necessary to establish stand-
21
ards under which a drug is generally rec-
22
ognized as safe and effective under section 
23
201(p)(1); 
24
04:32 Jun 29, 2019
H3443
43 
•HR 3443 IH
‘‘(ii) the information is submitted in a 
1
requestor-initiated request, but the re-
2
questor withdraws such request, in accord-
3
ance with withdrawal procedures estab-
4
lished by the Secretary, before the Sec-
5
retary issues the proposed order; 
6
‘‘(iii) the Secretary requests and ob-
7
tains the information under subsection (c) 
8
and such information is not submitted in 
9
relation to an order under subsection (b); 
10
or 
11
‘‘(iv) the information is of the type 
12
contained in raw datasets. 
13
‘‘(e) UPDATES TO DRUG LISTING INFORMATION.— 
14
A sponsor who makes a change to a drug subject to this 
15
section shall submit updated drug listing information for 
16
the drug in accordance with section 510(j) within 30 cal-
17
endar days of the date when the drug is first commercially 
18
marketed, except that a sponsor who was the order re-
19
questor with respect to an order subject to subsection 
20
(b)(5)(C) (or a licensee, assignee, or successor in interest 
21
of such requestor) shall submit updated drug listing infor-
22
mation on or before the date when the drug is first com-
23
mercially marketed. 
24
04:32 Jun 29, 2019
H3443
44 
•HR 3443 IH
‘‘(f) APPROVALS UNDER SECTION 505.—The provi-
1
sions of this section shall not be construed to preclude a 
2
person from seeking or maintaining the approval of an ap-
3
plication for a drug under sections 505(b)(1), 505(b)(2), 
4
and 505(j). A determination under this section that a drug 
5
is not subject to section 503(b)(1), is generally recognized 
6
as safe and effective under section 201(p)(1), and is not 
7
a new drug under section 201(p) shall constitute a finding 
8
that the drug is safe and effective that may be relied upon 
9
for purposes of an application under section 505(b)(2), so 
10
that the applicant shall be required to submit for purposes 
11
of such application only information needed to support any 
12
modification of the drug that is not covered by such deter-
13
mination under this section. 
14
‘‘(g) PUBLIC AVAILABILITY OF ADMINISTRATIVE OR-
15
DERS.—The Secretary shall establish, maintain, update 
16
(as determined necessary by the Secretary but no less fre-
17
quently than annually), and make publicly available, with 
18
respect to orders issued under this section— 
19
‘‘(1) a repository of each final order and in-
20
terim final order in effect, including the complete 
21
text of the order; and 
22
‘‘(2) a listing of all orders proposed and under 
23
development under subsection (b)(2), including— 
24
04:32 Jun 29, 2019
H3443
45 
•HR 3443 IH
‘‘(A) a brief description of each such order; 
1
and 
2
‘‘(B) the Secretary’s expectations, if re-
3
sources permit, for issuance of proposed orders 
4
over a 3-year period. 
5
‘‘(h) DEVELOPMENT ADVICE TO SPONSORS OR RE-
6
QUESTORS.—The Secretary shall establish procedures 
7
under which sponsors or requestors may meet with appro-
8
priate officials of the Food and Drug Administration to 
9
obtain advice on the studies and other information nec-
10
essary to support submissions under this section and other 
11
matters relevant to the regulation of nonprescription 
12
drugs and the development of new nonprescription drugs 
13
under this section. 
14
‘‘(i) PARTICIPATION OF MULTIPLE SPONSORS OR RE-
15
QUESTORS.—The Secretary shall establish procedures to 
16
facilitate efficient participation by multiple sponsors or re-
17
questors in proceedings under this section, including provi-
18
sion for joint meetings with multiple sponsors or reques-
19
tors or with organizations nominated by sponsors or re-
20
questors to represent their interests in a proceeding. 
21
‘‘(j) ELECTRONIC FORMAT.—All submissions under 
22
this section shall be in electronic format. 
23
‘‘(k) EFFECT
ON EXISTING REGULATIONS GOV-
24
ERNING NONPRESCRIPTION DRUGS.— 
25
04:32 Jun 29, 2019
H3443
46 
•HR 3443 IH
‘‘(1) REGULATIONS
OF
GENERAL
APPLICA-
1
BILITY
TO
NONPRESCRIPTION
DRUGS.—Except as 
2
provided in this subsection, nothing in this section 
3
supersedes regulations establishing general require-
4
ments for nonprescription drugs, including regula-
5
tions of general applicability contained in parts 201, 
6
250, and 330 of title 21, Code of Federal Regula-
7
tions, or any successor regulations. The Secretary 
8
shall establish or modify such regulations by means 
9
of rulemaking in accordance with section 553 of title 
10
5, United States Code. 
11
‘‘(2) REGULATIONS
ESTABLISHING
REQUIRE-
12
MENTS FOR SPECIFIC NONPRESCRIPTION DRUGS.— 
13
‘‘(A) The provisions of section 310.545 of 
14
title 21, Code of Federal Regulations, as in ef-
15
fect on the day before the date of the enact-
16
ment of this section, shall be deemed to be a 
17
final order under subsection (b). 
18
‘‘(B) Regulations in effect on the day be-
19
fore the date of the enactment of this section, 
20
establishing requirements for specific non-
21
prescription drugs marketed pursuant to this 
22
section (including such requirements in parts 
23
201 and 250 of title 21, Code of Federal Regu-
24
lations), shall be deemed to be final orders 
25
04:32 Jun 29, 2019
H3443
47 
•HR 3443 IH
under subsection (b), only as they apply to 
1
drugs— 
2
‘‘(i) subject to paragraph (1), (2), (3), 
3
or (4) of subsection (a); or 
4
‘‘(ii) otherwise subject to an order 
5
under this section. 
6
‘‘(3) WITHDRAWAL
OF
REGULATIONS.—The 
7
Secretary shall withdraw regulations establishing 
8
final monographs and the procedures governing the 
9
over-the-counter drug review under part 330 and 
10
other relevant parts of title 21, Code of Federal 
11
Regulations (as in effect on the day before the date 
12
of the enactment of this section), or make technical 
13
changes to such regulations to ensure conformity 
14
with appropriate terminology and cross references. 
15
Notwithstanding subchapter II of chapter 5 of title 
16
5, United States Code, any such withdrawal or tech-
17
nical changes shall be made without public notice 
18
and comment and shall be effective upon publication 
19
through notice in the Federal Register (or upon such 
20
date as specified in such notice). 
21
‘‘(l) GUIDANCE.—The Secretary shall issue guidance 
22
that specifies— 
23
04:32 Jun 29, 2019
H3443
48 
•HR 3443 IH
‘‘(1) the procedures and principles for formal 
1
meetings between the Secretary and sponsors or re-
2
questors for drugs subject to this section; 
3
‘‘(2) the format and content of data submis-
4
sions to the Secretary under this section; 
5
‘‘(3) the format of electronic submissions to the 
6
Secretary under this section; 
7
‘‘(4) consolidated proceedings for appeal and 
8
the procedures for such proceedings where appro-
9
priate; and 
10
‘‘(5) for minor changes in drugs, recommenda-
11
tions on how to comply with the requirements in or-
12
ders issued under subsection (c)(3). 
13
‘‘(m) RULE OF CONSTRUCTION.— 
14
‘‘(1) IN GENERAL.—This section shall not af-
15
fect the treatment or status of a nonprescription 
16
drug— 
17
‘‘(A) that is marketed without an applica-
18
tion approved under section 505 as of the date 
19
of the enactment of this section; 
20
‘‘(B) that is not subject to an order issued 
21
under this section; and 
22
‘‘(C) to which paragraphs (1), (2), (3), (4), 
23
or (5) of subsection (a) do not apply. 
24
04:32 Jun 29, 2019
H3443
49 
•HR 3443 IH
‘‘(2) TREATMENT
OF
PRODUCTS
PREVIOUSLY 
1
FOUND TO BE SUBJECT TO TIME AND EXTENT RE-
2
QUIREMENTS.— 
3
‘‘(A) Notwithstanding subsection (a), a 
4
drug described in subparagraph (B) may only 
5
be lawfully marketed, without an application 
6
approved under section 505, pursuant to an 
7
order issued under this section. 
8
‘‘(B) A drug described in this subpara-
9
graph is a drug which, prior to the date of the 
10
enactment of this section, the Secretary deter-
11
mined in a proposed or final rule to be ineligible 
12
for review under the OTC drug review (as such 
13
phrase ‘OTC drug review’ was used in section 
14
330.14 of title 21, Code of Federal Regulations, 
15
as in effect on the day before the date of the 
16
enactment of this section). 
17
‘‘(3) PRESERVATION OF AUTHORITY.— 
18
‘‘(A) Nothing in paragraph (1) shall be 
19
construed to preclude or limit the applicability 
20
of any provision of this Act other than this sec-
21
tion. 
22
‘‘(B) Nothing in subsection (a) shall be 
23
construed to prohibit the Secretary from issuing 
24
an order under this section finding a drug to be 
25
04:32 Jun 29, 2019
H3443
50 
•HR 3443 IH
not generally recognized as safe and effective 
1
under section 201(p)(1), as the Secretary deter-
2
mines appropriate. 
3
‘‘(n) INVESTIGATIONAL NEW DRUGS.—A drug is not 
4
subject to this section if an exemption for investigational 
5
use under section 505(i) is in effect for such drug. 
6
‘‘(o) INAPPLICABILITY OF PAPERWORK REDUCTION 
7
ACT.—Chapter 35 of title 44, United States Code, shall 
8
not apply to collections of information made under this 
9
section. 
10
‘‘(p) INAPPLICABILITY OF NOTICE AND COMMENT 
11
RULEMAKING
AND OTHER REQUIREMENTS.—The re-
12
quirements of subsection (b) shall apply with respect to 
13
orders issued under this section instead of the require-
14
ments of subchapter II of chapter 5 of title 5, United 
15
States Code. 
16
‘‘(q) DEFINITIONS.—In this section: 
17
‘‘(1) The term ‘nonprescription drug’ refers to 
18
a drug not subject to the requirements of section 
19
503(b)(1). 
20
‘‘(2) The term ‘sponsor’ refers to any person 
21
marketing, manufacturing, or processing a drug 
22
that— 
23
‘‘(A) is listed pursuant to section 510(j); 
24
and 
25
04:32 Jun 29, 2019
H3443
51 
•HR 3443 IH
‘‘(B) is or will be subject to an administra-
1
tive order under this section of the Food and 
2
Drug Administration. 
3
‘‘(3) The term ‘requestor’ refers to any person 
4
or group of persons marketing, manufacturing, proc-
5
essing, or developing a drug.’’. 
6
(b) GAO STUDY.—Not later than 4 years after the 
7
date of enactment of this Act, the Comptroller General 
8
of the United States shall submit a study to the Com-
9
mittee on Energy and Commerce of the House of Rep-
10
resentatives and the Committee on Health, Education, 
11
Labor, and Pensions of the Senate addressing the effec-
12
tiveness and overall impact of exclusivity under section 
13
505G of the Federal Food, Drug, and Cosmetic Act, as 
14
added by subsection (a), and section 586C of such Act 
15
(21 U.S.C. 360fff–3), including the impact of such exclu-
16
sivity on consumer access. Such study shall include— 
17
(1) an analysis of the impact of exclusivity 
18
under such section 505G for nonprescription drug 
19
products, including— 
20
(A) the number of nonprescription drug 
21
products that were granted exclusivity and the 
22
indication for which the nonprescription drug 
23
products were determined to be generally recog-
24
nized as safe and effective; 
25
04:32 Jun 29, 2019
H3443
52 
•HR 3443 IH
(B) whether the exclusivity for such drug 
1
products was granted for— 
2
(i) a new active ingredient (including 
3
any ester or salt of the active ingredient); 
4
or 
5
(ii) changes in the conditions of use of 
6
a drug, for which new human data studies 
7
conducted or sponsored by the requestor 
8
were essential; 
9
(C) whether, and to what extent, the exclu-
10
sivity impacted the requestor’s or sponsor’s de-
11
cision to develop the drug product; 
12
(D) an analysis of the implementation of 
13
the exclusivity provision in such section 505G, 
14
including— 
15
(i) the resources used by the Food 
16
and Drug Administration; 
17
(ii) the impact of such provision on 
18
innovation, as well as research and devel-
19
opment in the nonprescription drug mar-
20
ket; 
21
(iii) the impact of such provision on 
22
competition in the nonprescription drug 
23
market; 
24
04:32 Jun 29, 2019
H3443
53 
•HR 3443 IH
(iv) the impact of such provision on 
1
consumer access to nonprescription drug 
2
products; 
3
(v) the impact of such provision on 
4
the prices of nonprescription drug prod-
5
ucts; and 
6
(vi) whether the administrative orders 
7
initiated by requestors under such section 
8
505G have been sufficient to encourage the 
9
development of nonprescription drug prod-
10
ucts that would likely not be otherwise de-
11
veloped, or developed in as timely a man-
12
ner; and 
13
(E) whether the administrative orders ini-
14
tiated by requestors under such section 505G 
15
have been sufficient incentive to encourage in-
16
novation in the nonprescription drug market; 
17
and 
18
(2) an analysis of the impact of exclusivity 
19
under such section 586C for sunscreen ingredients, 
20
including— 
21
(A) the number of sunscreen ingredients 
22
that were granted exclusivity and the specific 
23
ingredient that was determined to be generally 
24
recognized as safe and effective; 
25
04:32 Jun 29, 2019
H3443
54 
•HR 3443 IH
(B) whether, and to what extent, the exclu-
1
sivity impacted the requestor’s or sponsor’s de-
2
cision to develop the sunscreen ingredient; 
3
(C) whether, and to what extent, the sun-
4
screen ingredient granted exclusivity had pre-
5
viously been available outside of the United 
6
States; 
7
(D) an analysis of the implementation of 
8
the exclusivity provision in such section 586C, 
9
including— 
10
(i) the resources used by the Food 
11
and Drug Administration; 
12
(ii) the impact of such provision on 
13
innovation, as well as research and devel-
14
opment in the sunscreen market; 
15
(iii) the impact of such provision on 
16
competition in the sunscreen market; 
17
(iv) the impact of such provision on 
18
consumer access to sunscreen products; 
19
(v) the impact of such provision on 
20
the prices of sunscreen products; and 
21
(vi) whether the administrative orders 
22
initiated by requestors under such section 
23
505G have been utilized by sunscreen in-
24
gredient sponsors and whether such proc-
25
04:32 Jun 29, 2019
H3443
55 
•HR 3443 IH
ess has been sufficient to encourage the 
1
development of sunscreen ingredients that 
2
would likely not be otherwise developed, or 
3
developed in as timely a manner; and 
4
(E) whether the administrative orders ini-
5
tiated by requestors under such section 586C 
6
have been sufficient incentive to encourage in-
7
novation in the sunscreen market. 
8
(c) CONFORMING AMENDMENT.—Section 751(d)(1) 
9
of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
10
379r(d)(1)) is amended— 
11
(1) in the matter preceding subparagraph (A)— 
12
(A) by striking ‘‘final regulation promul-
13
gated’’ and inserting ‘‘final order under section 
14
505G’’; and 
15
(B) by striking ‘‘and not misbranded’’; and 
16
(2) in subparagraph (A), by striking ‘‘regula-
17
tion in effect’’ and inserting ‘‘regulation or order in 
18
effect’’. 
19
SEC. 1002. MISBRANDING. 
20
Section 502 of the Federal Food, Drug, and Cosmetic 
21
Act (21 U.S.C. 352) is amended by adding at the end the 
22
following: 
23
‘‘(ee) If it is a nonprescription drug that is subject 
24
to section 505G, is not the subject of an application ap-
25
04:32 Jun 29, 2019
H3443
56 
•HR 3443 IH
proved under section 505, and does not comply with the 
1
requirements under section 505G. 
2
‘‘(ff) If it is a drug and it was manufactured, pre-
3
pared, propagated, compounded, or processed in a facility 
4
for which fees have not been paid as required by section 
5
744M.’’. 
6
SEC. 1003. DRUGS EXCLUDED FROM THE OVER-THE- 
7
COUNTER DRUG REVIEW. 
8
(a) IN GENERAL.—Nothing in this Act (or the 
9
amendments made by this Act) shall apply to any non-
10
prescription drug (as defined in section 505G(q) of the 
11
Federal Food, Drug, and Cosmetic Act, as added by sec-
12
tion 1001 of this Act) which was excluded by the Food 
13
and Drug Administration from the Over-the-Counter 
14
Drug Review in accordance with the paragraph numbered 
15
25 on page 9466 of volume 37 of the Federal Register, 
16
published on May 11, 1972. 
17
(b) RULE OF CONSTRUCTION.—Nothing in this sec-
18
tion shall be construed to preclude or limit the applica-
19
bility of any other provision of the Federal Food, Drug, 
20
and Cosmetic Act (21 U.S.C. 301 et seq.). 
21
SEC. 1004. TREATMENT OF SUNSCREEN INNOVATION ACT. 
22
(a) REVIEW OF NONPRESCRIPTION SUNSCREEN AC-
23
TIVE INGREDIENTS.— 
24
04:32 Jun 29, 2019
H3443
57 
•HR 3443 IH
(1) APPLICABILITY
OF
SECTION
505G
FOR 
1
PENDING SUBMISSIONS.— 
2
(A) IN GENERAL.—A sponsor of a non-
3
prescription sunscreen active ingredient or com-
4
bination of nonprescription sunscreen active in-
5
gredients that, as of the date of enactment of 
6
this Act, is subject to a proposed sunscreen 
7
order under section 586C of the Federal Food, 
8
Drug, and Cosmetic Act (21 U.S.C. 360fff–3) 
9
may elect, by means of giving written notifica-
10
tion to the Secretary of Health and Human 
11
Services within 180 calendar days of the enact-
12
ment of this Act, to transition into the review 
13
of such ingredient or combination of ingredients 
14
pursuant to the process set out in section 505G 
15
of the Federal Food, Drug, and Cosmetic Act, 
16
as added by section 1001 of this Act. 
17
(B) ELECTION EXERCISED.—Upon receipt 
18
by the Secretary of Health and Human Services 
19
of a timely notification under subparagraph 
20
(A)— 
21
(i) the proposed sunscreen order in-
22
volved is deemed to be a request for an 
23
order under subsection (b) of section 505G 
24
of the Federal Food, Drug, and Cosmetic 
25
04:32 Jun 29, 2019
H3443
58 
•HR 3443 IH
Act, as added by section 1001 of this Act; 
1
and 
2
(ii) such order is deemed to have been 
3
accepted 
for 
filing 
under 
subsection 
4
(b)(6)(A)(i) of such section 505G. 
5
(C) ELECTION NOT EXERCISED.—If a noti-
6
fication under subparagraph (A) is not received 
7
by the Secretary of Health and Human Services 
8
within 180 calendar days of the date of enact-
9
ment of this Act, the review of the proposed 
10
sunscreen order described in subparagraph 
11
(A)— 
12
(i) shall continue under section 586C 
13
of the Federal Food, Drug, and Cosmetic 
14
Act (21 U.S.C. 360fff–3); and 
15
(ii) shall not be eligible for review 
16
under section 505G, added by section 1001 
17
of this Act. 
18
(2) DEFINITIONS.—In this subsection, the 
19
terms ‘‘sponsor’’, ‘‘nonprescription’’, ‘‘sunscreen ac-
20
tive ingredient’’, and ‘‘proposed sunscreen order’’ 
21
have the meanings given to those terms in section 
22
586 of the Federal Food, Drug, and Cosmetic Act 
23
(21 U.S.C. 360fff). 
24
(b) AMENDMENTS TO SUNSCREEN PROVISIONS.— 
25
04:32 Jun 29, 2019
H3443
59 
•HR 3443 IH
(1) FINAL
SUNSCREEN
ORDERS.—Paragraph 
1
(3) of section 586C(e) of the Federal Food, Drug, 
2
and Cosmetic Act (21 U.S.C. 360fff–3(e)) is amend-
3
ed to read as follows: 
4
‘‘(3) RELATIONSHIP TO ORDERS UNDER SEC-
5
TION 505G.—A final sunscreen order shall be deemed 
6
to be a final order under section 505G.’’. 
7
(2) MEETINGS.—Paragraph (7) of section 
8
586C(b) of the Federal Food, Drug, and Cosmetic 
9
Act (21 U.S.C. 360fff–3(b)) is amended— 
10
(A) by striking ‘‘A sponsor may request’’ 
11
and inserting the following: 
12
‘‘(A) IN
GENERAL.—A sponsor may re-
13
quest’’; and 
14
(B) by adding at the end the following: 
15
‘‘(B) CONFIDENTIAL MEETINGS.—A spon-
16
sor may request one or more confidential meet-
17
ings with respect to a proposed sunscreen order, 
18
including a letter deemed to be a proposed sun-
19
screen order under paragraph (3), to discuss 
20
matters relating to data requirements to sup-
21
port a general recognition of safety and effec-
22
tiveness involving confidential information and 
23
public information related to such proposed 
24
sunscreen order, as appropriate. The Secretary 
25
04:32 Jun 29, 2019
H3443
60 
•HR 3443 IH
shall convene a confidential meeting with such 
1
sponsor in a reasonable time period. If a spon-
2
sor requests more than one confidential meeting 
3
for the same proposed sunscreen order, the Sec-
4
retary may refuse to grant an additional con-
5
fidential meeting request if the Secretary deter-
6
mines that such additional confidential meeting 
7
is not reasonably necessary for the sponsor to 
8
advance its proposed sunscreen order, or if the 
9
request for a confidential meeting fails to in-
10
clude sufficient information upon which to base 
11
a substantive discussion. The Secretary shall 
12
publish a post-meeting summary of each con-
13
fidential meeting under this subparagraph that 
14
does not disclose confidential commercial infor-
15
mation or trade secrets. This subparagraph 
16
does not authorize the disclosure of confidential 
17
commercial information or trade secrets subject 
18
to 552(b)(4) of title 5, United States Code, or 
19
section 1905 of title 18, United States Code.’’. 
20
(3) EXCLUSIVITY.—Section 586C of the Fed-
21
eral Food, Drug, and Cosmetic Act (21 U.S.C. 
22
360fff–3) is amended by adding at the end the fol-
23
lowing: 
24
‘‘(f) EXCLUSIVITY.— 
25
04:32 Jun 29, 2019
H3443
61 
•HR 3443 IH
‘‘(1) IN
GENERAL.—A final sunscreen order 
1
shall have the effect of authorizing solely the order 
2
requestor (or the licensees, assignees, or successors 
3
in interest of such requestor with respect to the sub-
4
ject of such request and listed under paragraph (5)) 
5
for a period of 18 months, to market a sunscreen in-
6
gredient under this section incorporating changes 
7
described in paragraph (2) subject to the limitations 
8
under paragraph (4), beginning on the date the re-
9
questor (or any licensees, assignees, or successors in 
10
interest of such requestor with respect to the subject 
11
of such request and listed under paragraph (5)) may 
12
lawfully market such sunscreen ingredient pursuant 
13
to the order. 
14
‘‘(2) CHANGES
DESCRIBED.—A change de-
15
scribed in this paragraph is a change subject to an 
16
order specified in paragraph (1) that permits a sun-
17
screen to contain an active sunscreen ingredient not 
18
previously incorporated in a marketed sunscreen list-
19
ed in paragraph (3). 
20
‘‘(3) MARKETED
SUNSCREEN.—The marketed 
21
sunscreen ingredients described in this paragraph 
22
are sunscreen ingredients— 
23
‘‘(A) marketed in accordance with a final 
24
monograph for sunscreen drug products set 
25
04:32 Jun 29, 2019
H3443
62 
•HR 3443 IH
forth at part 352 of title 21, Code of Federal 
1
Regulations (as published at 64 Fed. Reg. 
2
27687); or 
3
‘‘(B) marketed in accordance with a final 
4
order issued under this section. 
5
‘‘(4) LIMITATIONS ON EXCLUSIVITY.—Only one 
6
18-month period may be granted per ingredient 
7
under paragraph (1). 
8
‘‘(5) LISTING OF LICENSEES, ASSIGNEES, OR 
9
SUCCESSORS IN INTEREST.—Requestors shall submit 
10
to the Secretary at the time when a drug subject to 
11
such request is introduced or delivered for introduc-
12
tion into interstate commerce, a list of licensees, as-
13
signees, or successors in interest under paragraph 
14
(1).’’. 
15
(4) SUNSET PROVISION.—Subchapter I of chap-
16
ter V of the Federal Food, Drug, and Cosmetic Act 
17
(21 U.S.C. 360fff et seq.) is amended by adding at 
18
the end the following: 
19
‘‘SEC. 586H. SUNSET. 
20
‘‘This subchapter shall cease to be effective at the end 
21
of fiscal year 2022.’’. 
22
(5) 
TREATMENT
OF
FINAL
SUNSCREEN 
23
ORDER.—The Federal Food, Drug, and Cosmetic 
24
04:32 Jun 29, 2019
H3443
63 
•HR 3443 IH
Act is amended by striking section 586E of such Act 
1
(21 U.S.C. 360fff–5). 
2
(c) TREATMENT OF AUTHORITY REGARDING FINAL-
3
IZATION OF SUNSCREEN MONOGRAPH.— 
4
(1) IN GENERAL.— 
5
(A) REVISION
OF
FINAL
SUNSCREEN 
6
ORDER.—Not later than November 26, 2019, 
7
the Secretary of Health and Human Services 
8
(referred to in this subsection as the ‘‘Sec-
9
retary’’) shall amend and revise the final ad-
10
ministrative order concerning nonprescription 
11
sunscreen (referred to in this subsection as the 
12
‘‘sunscreen order’’) for which the content, prior 
13
to the date of enactment of this Act, was rep-
14
resented by the final monograph for sunscreen 
15
drug products set forth in part 352 of title 21, 
16
Code of Federal Regulations (as in effect on 
17
May 21, 1999). 
18
(B) ISSUANCE
OF
REVISED
SUNSCREEN 
19
ORDER; EFFECTIVE DATE.—A revised sunscreen 
20
order described in subparagraph (A) shall be— 
21
(i) issued in accordance with the pro-
22
cedures described in section 505G(c)(2) of 
23
the Federal Food, Drug, and Cosmetic 
24
Act; 
25
04:32 Jun 29, 2019
H3443
64 
•HR 3443 IH
(ii) issued in proposed form not later 
1
than May 28, 2019; 
2
(iii) effective not later than November 
3
26, 2020; and 
4
(iv) issued by the Secretary at least 1 
5
year prior to the effective date of the re-
6
vised order. 
7
(2) REPORTS.—If a revised sunscreen order 
8
issued under paragraph (1) does not include provi-
9
sions related to the effectiveness of various sun pro-
10
tection factor levels, and does not address all dosage 
11
forms known to the Secretary to be used in sun-
12
screens marketed in the United States without a 
13
new drug application approved under section 505 of 
14
the Federal Food, Drug, and Cosmetic Act (21 
15
U.S.C. 355), the Secretary shall submit a report to 
16
the Committee on Energy and Commerce of the 
17
House of Representatives and the Committee on 
18
Health, Education, Labor, and Pensions of the Sen-
19
ate on the rationale for omission of such provisions 
20
from such order, and a plan and timeline to compile 
21
any information necessary to address such provisions 
22
through such order. 
23
(d) TREATMENT OF NON-SUNSCREEN TIME AND EX-
24
TENT APPLICATIONS.— 
25
04:32 Jun 29, 2019
H3443
65 
•HR 3443 IH
(1) IN GENERAL.—Any application described in 
1
section 586F of the Federal Food, Drug, and Cos-
2
metic Act (21 U.S.C. 360fff–6) that was submitted 
3
to the Secretary pursuant to section 330.14 of title 
4
21, Code of Federal Regulations, as such provisions 
5
were in effect immediately prior to the date of enact-
6
ment date of this Act, shall be extinguished as of 
7
such date of enactment, subject to paragraph (2). 
8
(2) ORDER REQUEST.—Nothing in paragraph 
9
(1) precludes the submission of an order request 
10
under section 505G(b) of the Federal Food, Drug, 
11
and Cosmetic Act, as added by section 1001 of this 
12
Act, with respect to a drug that was the subject of 
13
an application extinguished under paragraph (1). 
14
SEC. 1005. ANNUAL UPDATE TO CONGRESS ON APPRO-
15
PRIATE PEDIATRIC INDICATION FOR CER-
16
TAIN OTC COUGH AND COLD DRUGS. 
17
(a) IN GENERAL.—Subject to subsection (c), the Sec-
18
retary of Health and Human Services shall, beginning not 
19
later than 1 year after the date of enactment of this Act, 
20
annually submit to the Committee on Energy and Com-
21
merce of the House of Representatives and the Committee 
22
on Health, Education, Labor, and Pensions of the Senate 
23
a letter describing the progress of the Food and Drug Ad-
24
ministration— 
25
04:32 Jun 29, 2019
H3443
66 
•HR 3443 IH
(1) in evaluating the cough and cold monograph 
1
described in subsection (b) with respect to children 
2
under age 6; and 
3
(2) as appropriate, revising such cough and cold 
4
monograph to address such children through the 
5
order process under section 505G(b) of the Federal 
6
Food, Drug, and Cosmetic Act, as added by section 
7
1001 of this Act. 
8
(b) COUGH AND COLD MONOGRAPH DESCRIBED.— 
9
The cough and cold monograph described in this sub-
10
section consists of the conditions under which nonprescrip-
11
tion drugs containing antitussive, expectorant, nasal de-
12
congestant, or antihistamine active ingredients (or com-
13
binations thereof) are generally recognized as safe and ef-
14
fective, as specified in part 341 of title 21, Code of Federal 
15
Regulations (as in effect immediately prior to the date of 
16
enactment of this Act), and included in an order deemed 
17
to be established under section 505G(b) of the Federal 
18
Food, Drug, and Cosmetic Act, as added by section 1001 
19
of this Act. 
20
(c) DURATION
OF AUTHORITY.—The requirement 
21
under subsection (a) shall terminate as of the date of a 
22
letter submitted by the Secretary of Health and Human 
23
Services pursuant to such subsection in which the Sec-
24
retary indicates that the Food and Drug Administration 
25
04:32 Jun 29, 2019
H3443
67 
•HR 3443 IH
has completed its evaluation and revised, in a final order, 
1
as applicable, the cough and cold monograph as described 
2
in subsection (a)(2). 
3
SEC. 1006. TECHNICAL CORRECTIONS. 
4
(a) 
IMPORTS
AND
EXPORTS.—Section 
5
801(e)(4)(E)(iii) of the Federal Food, Drug, and Cosmetic 
6
Act (21 U.S.C. 381(e)(4)(E)(iii)) is amended by striking 
7
‘‘subparagraph’’ each place such term appears and insert-
8
ing ‘‘paragraph’’. 
9
(b) FDA REAUTHORIZATION ACT OF 2017.— 
10
(1) IN
GENERAL.—Section 905(b)(4) of the 
11
FDA Reauthorization Act of 2017 (Public Law 115– 
12
52) is amended by striking ‘‘Section 744H(e)(2)(B)’’ 
13
and inserting ‘‘Section 744H(f)(2)(B)’’. 
14
(2) EFFECTIVE DATE.—The amendment made 
15
by paragraph (1) shall take effect as of the enact-
16
ment of the FDA Reauthorization Act of 2017 
17
(Public Law 115–52). 
18
TITLE II—USER FEES 
19
SEC. 2001. SHORT TITLE; FINDING. 
20
(a) SHORT TITLE.—This title may be cited as the 
21
‘‘Over-the-Counter Monograph User Fee Act of 2019’’. 
22
(b) FINDING.—The Congress finds that the fees au-
23
thorized by the amendments made in this title will be dedi-
24
cated to OTC monograph drug activities, as set forth in 
25
04:32 Jun 29, 2019
H3443
68 
•HR 3443 IH
the goals identified for purposes of part 10 of subchapter 
1
C of chapter VII of the Federal Food, Drug, and Cosmetic 
2
Act, in the letters from the Secretary of Health and 
3
Human Services to the Chairman of the Committee on 
4
Health, Education, Labor, and Pensions of the Senate and 
5
the Chairman of the Committee on Energy and Commerce 
6
of the House of Representatives, as set forth in the Con-
7
gressional Record. 
8
SEC. 2002. FEES RELATING TO OVER-THE-COUNTER DRUGS. 
9
Subchapter C of chapter VII of the Federal Food, 
10
Drug, and Cosmetic Act (21 U.S.C. 379f et seq.) is 
11
amended by inserting after part 9 the following: 
12
‘‘PART 10—FEES RELATING TO OVER-THE- 
13
COUNTER DRUGS 
14
‘‘SEC. 744L. DEFINITIONS. 
15
‘‘In this part: 
16
‘‘(1) The term ‘affiliate’ means a business enti-
17
ty that has a relationship with a second business en-
18
tity if, directly or indirectly— 
19
‘‘(A) one business entity controls, or has 
20
the power to control, the other business entity; 
21
or 
22
‘‘(B) a third party controls, or has power 
23
to control, both of the business entities. 
24
04:32 Jun 29, 2019
H3443
69 
•HR 3443 IH
‘‘(2) The term ‘contract manufacturing organi-
1
zation facility’ means an OTC monograph drug facil-
2
ity where neither the owner of such manufacturing 
3
facility nor any affiliate of such owner or facility 
4
sells the OTC monograph drug produced at such fa-
5
cility directly to wholesalers, retailers, or consumers 
6
in the United States. 
7
‘‘(3) The term ‘costs of resources allocated for 
8
OTC monograph drug activities’ means the expenses 
9
in connection with OTC monograph drug activities 
10
for— 
11
‘‘(A) officers and employees of the Food 
12
and Drug Administration, contractors of the 
13
Food and Drug Administration, advisory com-
14
mittees, and costs related to such officers, em-
15
ployees, and committees and costs related to 
16
contracts with such contractors; 
17
‘‘(B) management of information, and the 
18
acquisition, maintenance, and repair of com-
19
puter resources; 
20
‘‘(C) leasing, maintenance, renovation, and 
21
repair of facilities and acquisition, maintenance, 
22
and repair of fixtures, furniture, scientific 
23
equipment, and other necessary materials and 
24
supplies; and 
25
04:32 Jun 29, 2019
H3443
70 
•HR 3443 IH
‘‘(D) collecting fees under section 744M 
1
and accounting for resources allocated for OTC 
2
monograph drug activities. 
3
‘‘(4) The term ‘FDA establishment identifier’ is 
4
the unique number automatically generated by Food 
5
and Drug Administration’s Field Accomplishments 
6
and Compliance Tracking System (FACTS) (or any 
7
successor system). 
8
‘‘(5) The term ‘OTC monograph drug’ means a 
9
nonprescription drug without an approved new drug 
10
application which is governed by the provisions of 
11
section 505G. 
12
‘‘(6) The term ‘OTC monograph drug activities’ 
13
means activities of the Secretary associated with 
14
OTC monograph drugs and inspection of facilities 
15
associated with such products, including the fol-
16
lowing activities: 
17
‘‘(A) The activities necessary for review 
18
and evaluation of OTC monographs and OTC 
19
monograph order requests, including— 
20
‘‘(i) orders proposing or finalizing ap-
21
plicable conditions of use for OTC mono-
22
graph drugs; 
23
‘‘(ii) orders affecting status regarding 
24
general recognition of safety and effective-
25
04:32 Jun 29, 2019
H3443
71 
•HR 3443 IH
ness of an OTC monograph ingredient or 
1
combination of ingredients under specified 
2
conditions of use; 
3
‘‘(iii) all OTC monograph drug devel-
4
opment and review activities, including 
5
intra-agency collaboration; 
6
‘‘(iv) regulation and policy develop-
7
ment activities related to OTC monograph 
8
drugs; 
9
‘‘(v) development of product standards 
10
for products subject to review and evalua-
11
tion; 
12
‘‘(vi) meetings referred to in section 
13
505G(i); 
14
‘‘(vii) review of labeling prior to 
15
issuance of orders related to OTC mono-
16
graph drugs or conditions of use; and 
17
‘‘(viii) regulatory science activities re-
18
lated to OTC monograph drugs. 
19
‘‘(B) Inspections related to OTC mono-
20
graph drugs. 
21
‘‘(C) Monitoring of clinical and other re-
22
search conducted in connection with OTC 
23
monograph drugs. 
24
04:32 Jun 29, 2019
H3443
72 
•HR 3443 IH
‘‘(D) Safety activities with respect to OTC 
1
monograph drugs, including— 
2
‘‘(i) collecting, developing, and review-
3
ing safety information on OTC monograph 
4
drugs, including adverse event reports; 
5
‘‘(ii) developing and using improved 
6
adverse event data-collection systems, in-
7
cluding information technology systems; 
8
and 
9
‘‘(iii) developing and using improved 
10
analytical tools to assess potential safety 
11
risks, including access to external data-
12
bases. 
13
‘‘(E) Other activities necessary for imple-
14
mentation of section 505G. 
15
‘‘(7) The term ‘OTC monograph order request’ 
16
means a request for an order submitted under sec-
17
tion 505G(b)(5). 
18
‘‘(8) The term ‘Tier 1 OTC monograph order 
19
request’ means any OTC monograph order request 
20
not determined to be a Tier 2 OTC monograph 
21
order request. 
22
‘‘(9)(A) The term ‘Tier 2 OTC monograph 
23
order request’ means, subject to subparagraph (B), 
24
an OTC monograph order request for— 
25
04:32 Jun 29, 2019
H3443
73 
•HR 3443 IH
‘‘(i) the reordering of existing information 
1
in the drug facts label of an OTC monograph 
2
drug; 
3
‘‘(ii) the addition of information to the 
4
other information section of the drug facts label 
5
of an OTC monograph drug, as limited by sec-
6
tion 201.66(c)(7) of title 21, Code of Federal 
7
Regulations (or any successor regulations); 
8
‘‘(iii) modification to the directions for use 
9
section of the drug facts label of an OTC mono-
10
graph drug, if such changes conform to changes 
11
made pursuant to section 505G(c)(3)(A); 
12
‘‘(iv) the standardization of the concentra-
13
tion or dose of a specific finalized ingredient 
14
within a particular finalized monograph; 
15
‘‘(v) a change to ingredient nomenclature 
16
to align with nomenclature of a standards-set-
17
ting organization; or 
18
‘‘(vi) addition of an interchangeable term 
19
in accordance with section 330.1 of title 21, 
20
Code of Federal Regulations (or any successor 
21
regulations). 
22
‘‘(B) The Secretary may, based on program im-
23
plementation experience or other factors found ap-
24
propriate by the Secretary, characterize any OTC 
25
04:32 Jun 29, 2019
H3443
74 
•HR 3443 IH
monograph order request as a Tier 2 OTC mono-
1
graph order request (including recharacterizing a re-
2
quest from Tier 1 to Tier 2) and publish such deter-
3
mination in a proposed order issued pursuant to sec-
4
tion 505G. 
5
‘‘(10)(A) The term ‘OTC monograph drug facil-
6
ity’ means a foreign or domestic business or other 
7
entity that— 
8
‘‘(i) is— 
9
‘‘(I) under one management, either di-
10
rect or indirect; and 
11
‘‘(II) at one geographic location or ad-
12
dress engaged in manufacturing or proc-
13
essing the finished dosage form of an OTC 
14
monograph drug; 
15
‘‘(ii) includes a finished dosage form man-
16
ufacturer facility in a contractual relationship 
17
with the sponsor of one or more OTC mono-
18
graph drugs to manufacture or process such 
19
drugs; and 
20
‘‘(iii) does not include a business or other 
21
entity whose only manufacturing or processing 
22
activities are one or more of the following: pro-
23
duction of clinical research supplies, testing, or 
24
placement of outer packaging on packages con-
25
04:32 Jun 29, 2019
H3443
75 
•HR 3443 IH
taining multiple products, for such purposes as 
1
creating multipacks, when each monograph 
2
drug product contained within the overpack-
3
aging is already in a final packaged form prior 
4
to placement in the outer overpackaging. 
5
‘‘(B) For purposes of subparagraph (A)(i)(II), 
6
separate buildings or locations within close proximity 
7
are considered to be at one geographic location or 
8
address if the activities conducted in such buildings 
9
or locations are— 
10
‘‘(i) closely related to the same business 
11
enterprise; 
12
‘‘(ii) under the supervision of the same 
13
local management; and 
14
‘‘(iii) under a single FDA establishment 
15
identifier and capable of being inspected by the 
16
Food and Drug Administration during a single 
17
inspection. 
18
‘‘(C) If a business or other entity would meet 
19
criteria specified in subparagraph (A), but for being 
20
under multiple management, the business or other 
21
entity is deemed to constitute multiple facilities, one 
22
per management entity, for purposes of this para-
23
graph. 
24
04:32 Jun 29, 2019
H3443
76 
•HR 3443 IH
‘‘(11) The term ‘OTC monograph drug meet-
1
ing’ means any meeting regarding the content of a 
2
proposed OTC monograph order request. 
3
‘‘(12) The term ‘person’ includes an affiliate of 
4
a person. 
5
‘‘(13) The terms ‘requestor’ and ‘sponsor’ have 
6
the meanings given such terms in section 505G. 
7
‘‘SEC. 744M. AUTHORITY TO ASSESS AND USE OTC MONO-
8
GRAPH FEES. 
9
‘‘(a) TYPES OF FEES.—Beginning with fiscal year 
10
2019, the Secretary shall assess and collect fees in accord-
11
ance with this section as follows: 
12
‘‘(1) FACILITY FEE.— 
13
‘‘(A) IN
GENERAL.—Each person that 
14
owns a facility identified as an OTC monograph 
15
drug facility on December 31 of the fiscal year 
16
or at any time during the preceding 12-month 
17
period shall be assessed an annual fee for each 
18
such facility as determined under subsection 
19
(c). 
20
‘‘(B) EXCEPTIONS.— 
21
‘‘(i) A fee shall not be assessed under 
22
subparagraph (A) if the identified OTC 
23
monograph drug facility— 
24
04:32 Jun 29, 2019
H3443
77 
•HR 3443 IH
‘‘(I) has ceased all activities re-
1
lated to OTC monograph drugs prior 
2
to January 31, 2019, for the first pro-
3
gram year, and December 31 of the 
4
fiscal year for subsequent fiscal years; 
5
and 
6
‘‘(II) has updated its registration 
7
to reflect such change under the re-
8
quirements for drug establishment 
9
registration set forth in section 510. 
10
‘‘(ii) The amount of the fee for a con-
11
tract manufacturing organization facility 
12
shall be equal to two-thirds of the amount 
13
of the fee for an OTC monograph drug fa-
14
cility that is not a contract manufacturing 
15
organization facility. 
16
‘‘(C) AMOUNT.—The amount of fees estab-
17
lished under subparagraph (A) shall be estab-
18
lished under subsection (c). 
19
‘‘(D) DUE DATE.— 
20
‘‘(i) FOR FIRST PROGRAM YEAR.—For 
21
fiscal year 2019, the facility fees required 
22
under subparagraph (A) shall be due 45 
23
calendar days after publication of the Fed-
24
04:32 Jun 29, 2019
H3443
78 
•HR 3443 IH
eral Register notice provided for under 
1
subsection (c)(4)(A). 
2
‘‘(ii) SUBSEQUENT
FISCAL
YEARS.— 
3
For each fiscal year after fiscal year 2019, 
4
the facility fees required under subpara-
5
graph (A) shall be due on the later of— 
6
‘‘(I) the first business day of 
7
June of such year; or 
8
‘‘(II) the first business day after 
9
the enactment of an appropriations 
10
Act providing for the collection and 
11
obligation of fees under this section 
12
for such year. 
13
‘‘(2) 
OTC 
MONOGRAPH
ORDER
REQUEST 
14
FEE.— 
15
‘‘(A) IN GENERAL.—Each person that sub-
16
mits an OTC monograph order request shall be 
17
subject to a fee for an OTC monograph order 
18
request. The amount of such fee shall be— 
19
‘‘(i) for a Tier 1 OTC monograph 
20
order request, $500,000, adjusted for in-
21
flation for the fiscal year (as determined 
22
under subsection (c)(1)(B)); and 
23
‘‘(ii) for a Tier 2 OTC monograph 
24
order request, $100,000 adjusted for infla-
25
04:32 Jun 29, 2019
H3443
79 
•HR 3443 IH
tion for the fiscal year (as determined 
1
under subsection (c)(1)(B)). 
2
‘‘(B) DUE
DATE.—The OTC monograph 
3
order request fees required under subparagraph 
4
(A) shall be due on the date of submission of 
5
the OTC monograph order request. 
6
‘‘(C) EXCEPTION
FOR
CERTAIN
SAFETY 
7
CHANGES.—A person who is named as the re-
8
questor in an OTC monograph order shall not 
9
be subject to a fee under subparagraph (A) if 
10
the Secretary finds that the OTC monograph 
11
order request seeks to change the drug facts la-
12
beling of an OTC monograph drug in a way 
13
that would add to or strengthen— 
14
‘‘(i) a contraindication, warning, or 
15
precaution; 
16
‘‘(ii) a statement about risk associated 
17
with misuse or abuse; or 
18
‘‘(iii) an instruction about dosage and 
19
administration that is intended to increase 
20
the safe use of the OTC monograph drug. 
21
‘‘(D) REFUND OF FEE IF ORDER REQUEST 
22
IS RECATEGORIZED AS A TIER 2 OTC MONO-
23
GRAPH ORDER REQUEST.—If the Secretary de-
24
termines that an OTC monograph request ini-
25
04:32 Jun 29, 2019
H3443
80 
•HR 3443 IH
tially characterized as Tier 1 shall be re-charac-
1
terized as a Tier 2 OTC monograph order re-
2
quest, and the requestor has paid a Tier 1 fee 
3
in accordance with subparagraph (A)(i), the 
4
Secretary shall refund the requestor the dif-
5
ference between the Tier 1 and Tier 2 fees de-
6
termined under subparagraphs (A)(i) and 
7
(A)(ii), respectively. 
8
‘‘(E) REFUND OF FEE IF ORDER REQUEST 
9
REFUSED FOR FILING OR WITHDRAWN BEFORE 
10
FILING.—The Secretary shall refund 75 percent 
11
of the fee paid under subparagraph (B) for any 
12
order request which is refused for filing or was 
13
withdrawn before being accepted or refused for 
14
filing. 
15
‘‘(F) FEES
FOR
ORDER
REQUESTS
PRE-
16
VIOUSLY REFUSED FOR FILING OR WITHDRAWN 
17
BEFORE
FILING.—An OTC monograph order 
18
request that was submitted but was refused for 
19
filing, or was withdrawn before being accepted 
20
or refused for filing, shall be subject to the full 
21
fee under subparagraph (A) upon being resub-
22
mitted or filed over protest. 
23
‘‘(G) REFUND OF FEE IF ORDER REQUEST 
24
WITHDRAWN.—If an order request is withdrawn 
25
04:32 Jun 29, 2019
H3443
81 
•HR 3443 IH
after the order request was filed, the Secretary 
1
may refund the fee or a portion of the fee if no 
2
substantial work was performed on the order 
3
request after the application was filed. The Sec-
4
retary shall have the sole discretion to refund a 
5
fee or a portion of the fee under this subpara-
6
graph. A determination by the Secretary con-
7
cerning a refund under this subparagraph shall 
8
not be reviewable. 
9
‘‘(3) REFUNDS.— 
10
‘‘(A) IN
GENERAL.—Other than refunds 
11
provided pursuant to any of subparagraphs (D) 
12
through (G) of paragraph (2), the Secretary 
13
shall not refund any fee paid under paragraph 
14
(1) except as provided in subparagraph (B). 
15
‘‘(B) DISPUTES
CONCERNING
FEES.—To 
16
qualify for the return of a fee claimed to have 
17
been paid in error under paragraph (1) or (2), 
18
a person shall submit to the Secretary a written 
19
request justifying such return within 180 cal-
20
endar days after such fee was paid. 
21
‘‘(4) NOTICE.—Within the timeframe specified 
22
in subsection (c), the Secretary shall publish in the 
23
Federal Register the amount of the fees under para-
24
graph (1) for such fiscal year. 
25
04:32 Jun 29, 2019
H3443
82 
•HR 3443 IH
‘‘(b) FEE REVENUE AMOUNTS.— 
1
‘‘(1) FISCAL YEAR 2019.—For fiscal year 2019, 
2
fees under subsection (a)(1) shall be established to 
3
generate a total facility fee revenue amount equal to 
4
the sum of— 
5
‘‘(A) the annual base revenue for fiscal 
6
year 2019 (as determined under paragraph 
7
(3)); 
8
‘‘(B) the dollar amount equal to the oper-
9
ating reserve adjustment for the fiscal year, if 
10
applicable (as determined under subsection 
11
(c)(2)); and 
12
‘‘(C) additional direct cost adjustments (as 
13
determined under subsection (c)(3)). 
14
‘‘(2) SUBSEQUENT FISCAL YEARS.—For each of 
15
the fiscal years 2020 through 2023, fees under sub-
16
section (a)(1) shall be established to generate a total 
17
facility fee revenue amount equal to the sum of— 
18
‘‘(A) the annual base revenue for the fiscal 
19
year (as determined under paragraph (3)); 
20
‘‘(B) the dollar amount equal to the infla-
21
tion adjustment for the fiscal year (as deter-
22
mined under subsection (c)(1)); 
23
‘‘(C) the dollar amount equal to the oper-
24
ating reserve adjustment for the fiscal year, if 
25
04:32 Jun 29, 2019
H3443
83 
•HR 3443 IH
applicable (as determined under subsection 
1
(c)(2)); 
2
‘‘(D) additional direct cost adjustments (as 
3
determined under subsection (c)(3)); and 
4
‘‘(E) additional dollar amounts for each 
5
fiscal year as follows: 
6
‘‘(i) $7,000,000 for fiscal year 2020. 
7
‘‘(ii) $6,000,000 for fiscal year 2021. 
8
‘‘(iii) $7,000,000 for fiscal year 2022. 
9
‘‘(iv) $3,000,000 for fiscal year 2023. 
10
‘‘(3) ANNUAL BASE REVENUE.—For purposes 
11
of paragraphs (1)(A) and (2)(A), the dollar amount 
12
of the annual base revenue for a fiscal year shall 
13
be— 
14
‘‘(A) for fiscal year 2019, $8,000,000; and 
15
‘‘(B) for fiscal years 2020 through 2023, 
16
the dollar amount of the total revenue amount 
17
established under this subsection for the pre-
18
vious fiscal year, not including any adjustments 
19
made under subsection (c)(2) or (c)(3). 
20
‘‘(c) ADJUSTMENTS; ANNUAL FEE SETTING.— 
21
‘‘(1) INFLATION ADJUSTMENT.— 
22
‘‘(A) IN GENERAL.—For purposes of sub-
23
section (b)(2)(B), the dollar amount of the in-
24
flation adjustment to the annual base revenue 
25
04:32 Jun 29, 2019
H3443
84 
•HR 3443 IH
for fiscal year 2020 and each subsequent fiscal 
1
year shall be equal to the product of— 
2
‘‘(i) such annual base revenue for the 
3
fiscal year under subsection (b)(2); and 
4
‘‘(ii) the inflation adjustment percent-
5
age under subparagraph (C). 
6
‘‘(B) OTC MONOGRAPH ORDER REQUEST 
7
FEES.—For purposes of subsection (a)(2), the 
8
dollar amount of the inflation adjustment to the 
9
fee for OTC monograph order requests for fis-
10
cal year 2020 and each subsequent fiscal year 
11
shall be equal to the product of— 
12
‘‘(i) the applicable fee under sub-
13
section (a)(2) for the preceding fiscal year; 
14
and 
15
‘‘(ii) the inflation adjustment percent-
16
age under subparagraph (C). 
17
‘‘(C) INFLATION
ADJUSTMENT
PERCENT-
18
AGE.—The inflation adjustment percentage 
19
under this subparagraph for a fiscal year is 
20
equal to— 
21
‘‘(i) for each of fiscal years 2020 and 
22
2021, the average annual percent change 
23
that occurred in the Consumer Price Index 
24
for urban consumers (Washington-Balti-
25
04:32 Jun 29, 2019
H3443
85 
•HR 3443 IH
more, DC–MD–VA–WV; Not Seasonally 
1
Adjusted; All items; Annual Index) for the 
2
first 3 years of the preceding 4 years of 
3
available data; and 
4
‘‘(ii) for each of fiscal years 2022 and 
5
2023, the sum of— 
6
‘‘(I) the average annual percent 
7
change in the cost, per full-time equiv-
8
alent position of the Food and Drug 
9
Administration, of all personnel com-
10
pensation and benefits paid with re-
11
spect to such positions for the first 3 
12
years of the preceding 4 fiscal years, 
13
multiplied by the proportion of per-
14
sonnel 
compensation 
and 
benefits 
15
costs to total costs of OTC mono-
16
graph drug activities for the first 3 
17
years of the preceding 4 fiscal years; 
18
and 
19
‘‘(II) the average annual percent 
20
change that occurred in the Consumer 
21
Price Index for urban consumers 
22
(Washington-Baltimore, DC–MD–VA– 
23
WV; Not Seasonally Adjusted; All 
24
items; Annual Index) for the first 3 
25
04:32 Jun 29, 2019
H3443
86 
•HR 3443 IH
years of the preceding 4 years of 
1
available data multiplied by the pro-
2
portion of all costs other than per-
3
sonnel 
compensation 
and 
benefits 
4
costs to total costs of OTC mono-
5
graph drug activities for the first 3 
6
years of the preceding 4 fiscal years. 
7
‘‘(2) OPERATING RESERVE ADJUSTMENT.— 
8
‘‘(A) IN GENERAL.—For fiscal year 2019 
9
and subsequent fiscal years, for purposes of 
10
subsections (b)(1)(B) and (b)(2)(C), the Sec-
11
retary may, in addition to adjustments under 
12
paragraph (1), further increase the fee revenue 
13
and fees if such an adjustment is necessary to 
14
provide operating reserves of carryover user 
15
fees for OTC monograph drug activities for not 
16
more than the number of weeks specified in 
17
subparagraph (B). 
18
‘‘(B) NUMBER OF WEEKS.—The number of 
19
weeks specified in this subparagraph is— 
20
‘‘(i) 3 weeks for fiscal year 2019; 
21
‘‘(ii) 7 weeks for fiscal year 2020; 
22
‘‘(iii) 10 weeks for fiscal year 2021; 
23
‘‘(iv) 10 weeks for fiscal year 2022; 
24
and 
25
04:32 Jun 29, 2019
H3443
87 
•HR 3443 IH
‘‘(v) 10 weeks for fiscal year 2023. 
1
‘‘(C) DECREASE.—If the Secretary has 
2
carryover balances for such process in excess of 
3
10 weeks of the operating reserves referred to 
4
in subparagraph (A), the Secretary shall de-
5
crease the fee revenue and fees referred to in 
6
such subparagraph to provide for not more than 
7
10 weeks of such operating reserves. 
8
‘‘(D) RATIONALE
FOR
ADJUSTMENT.—If 
9
an adjustment under this paragraph is made, 
10
the rationale for the amount of the increase or 
11
decrease (as applicable) in fee revenue and fees 
12
shall be contained in the annual Federal Reg-
13
ister notice under paragraph (4) establishing 
14
fee revenue and fees for the fiscal year involved. 
15
‘‘(3) 
ADDITIONAL
DIRECT
COST
ADJUST-
16
MENT.—The Secretary shall, in addition to adjust-
17
ments under paragraphs (1) and (2), further in-
18
crease the fee revenue and fees for purposes of sub-
19
section (b)(2)(D) by an amount equal to— 
20
‘‘(A) $14,000,000 for fiscal year 2019; 
21
‘‘(B) $7,000,000 for fiscal year 2020; 
22
‘‘(C) $4,000,000 for fiscal year 2021; 
23
‘‘(D) $3,000,000 for fiscal year 2022; and 
24
‘‘(E) $3,000,000 for fiscal year 2023. 
25
04:32 Jun 29, 2019
H3443
88 
•HR 3443 IH
‘‘(4) ANNUAL FEE SETTING.— 
1
‘‘(A) FISCAL
YEAR
2019.—The Secretary 
2
shall, not later than the second Monday in 
3
March of 2019— 
4
‘‘(i) establish OTC monograph drug 
5
facility fees for fiscal year 2019 under sub-
6
section (a), based on the revenue amount 
7
for such year under subsection (b) and the 
8
adjustments provided under this sub-
9
section; and 
10
‘‘(ii) publish fee revenue, facility fees, 
11
and OTC monograph order requests in the 
12
Federal Register. 
13
‘‘(B) SUBSEQUENT
FISCAL
YEARS.—The 
14
Secretary shall, not later than the second Mon-
15
day in March of each fiscal year that begins 
16
after September 30, 2019— 
17
‘‘(i) establish for each such fiscal 
18
year, based on the revenue amounts under 
19
subsection (b) and the adjustments pro-
20
vided under this subsection— 
21
‘‘(I) OTC monograph drug facil-
22
ity fees under subsection (a)(1); and 
23
04:32 Jun 29, 2019
H3443
89 
•HR 3443 IH
‘‘(II) OTC monograph order re-
1
quest fees under subsection (a)(2); 
2
and 
3
‘‘(ii) 
publish 
such 
fee 
revenue 
4
amounts, facility fees, and OTC mono-
5
graph order request fees in the Federal 
6
Register. 
7
‘‘(d) IDENTIFICATION OF FACILITIES.—Each person 
8
that owns an OTC monograph drug facility shall submit 
9
to the Secretary the information required under this sub-
10
section each year. Such information shall, for each fiscal 
11
year— 
12
‘‘(1) be submitted as part of the requirements 
13
for drug establishment registration set forth in sec-
14
tion 510; and 
15
‘‘(2) include for each such facility, at a min-
16
imum, identification of the facility’s business oper-
17
ation as that of an OTC monograph drug facility. 
18
‘‘(e) EFFECT OF FAILURE TO PAY FEES.— 
19
‘‘(1) OTC MONOGRAPH DRUG FACILITY FEE.— 
20
‘‘(A) IN GENERAL.—Failure to pay the fee 
21
under subsection (a)(1) within 20 calendar days 
22
of the due date as specified in subparagraph 
23
(D) of such subsection shall result in the fol-
24
lowing: 
25
04:32 Jun 29, 2019
H3443
90 
•HR 3443 IH
‘‘(i) The Secretary shall place the fa-
1
cility on a publicly available arrears list. 
2
‘‘(ii) All OTC monograph drugs man-
3
ufactured in such a facility or containing 
4
an ingredient manufactured in such a facil-
5
ity shall be deemed misbranded under sec-
6
tion 502(ff). 
7
‘‘(B) APPLICATION
OF
PENALTIES.—The 
8
penalties under this paragraph shall apply until 
9
the fee established by subsection (a)(1) is paid. 
10
‘‘(2) ORDER REQUESTS.—An OTC monograph 
11
order request submitted by a person subject to fees 
12
under subsection (a) shall be considered incomplete 
13
and shall not be accepted for filing by the Secretary 
14
until all fees owed by such person under this section 
15
have been paid. 
16
‘‘(3) MEETINGS.—A person subject to fees 
17
under this section shall be considered ineligible for 
18
OTC monograph drug meetings until all such fees 
19
owed by such person have been paid. 
20
‘‘(f) CREDITING AND AVAILABILITY OF FEES.— 
21
‘‘(1) IN GENERAL.—Fees authorized under sub-
22
section (a) shall be collected and available for obliga-
23
tion only to the extent and in the amount provided 
24
in advance in appropriations Acts. Such fees are au-
25
04:32 Jun 29, 2019
H3443
91 
•HR 3443 IH
thorized to remain available until expended. Such 
1
sums as may be necessary may be transferred from 
2
the Food and Drug Administration salaries and ex-
3
penses appropriation account without fiscal year lim-
4
itation to such appropriation account for salaries 
5
and expenses with such fiscal year limitation. The 
6
sums transferred shall be available solely for OTC 
7
monograph drug activities. 
8
‘‘(2) 
COLLECTIONS
AND
APPROPRIATION 
9
ACTS.— 
10
‘‘(A) IN
GENERAL.—Subject to subpara-
11
graph (C), the fees authorized by this section 
12
shall be collected and available in each fiscal 
13
year in an amount not to exceed the amount 
14
specified in appropriation Acts, or otherwise 
15
made available for obligation, for such fiscal 
16
year. 
17
‘‘(B) USE
OF
FEES
AND
LIMITATION.— 
18
The fees authorized by this section shall be 
19
available to defray increases in the costs of the 
20
resources allocated for OTC monograph drug 
21
activities (including increases in such costs for 
22
an additional number of full-time equivalent po-
23
sitions in the Department of Health and 
24
Human Services to be engaged in such activi-
25
04:32 Jun 29, 2019
H3443
92 
•HR 3443 IH
ties), only if the Secretary allocates for such 
1
purpose an amount for such fiscal year (exclud-
2
ing amounts from fees collected under this sec-
3
tion) no less than $12,000,000, multiplied by 
4
the adjustment factor applicable to the fiscal 
5
year involved under subsection (c)(1). 
6
‘‘(C) COMPLIANCE.—The Secretary shall 
7
be considered to have met the requirements of 
8
subparagraph (B) in any fiscal year if the costs 
9
funded by appropriations and allocated for OTC 
10
monograph drug activities are not more than 15 
11
percent below the level specified in such sub-
12
paragraph. 
13
‘‘(D) PROVISION FOR EARLY PAYMENTS IN 
14
SUBSEQUENT YEARS.—Payment of fees author-
15
ized under this section for a fiscal year (after 
16
fiscal year 2019), prior to the due date for such 
17
fees, may be accepted by the Secretary in ac-
18
cordance with authority provided in advance in 
19
a prior year appropriations Act. 
20
‘‘(3) AUTHORIZATION
OF
APPROPRIATIONS.— 
21
For each of the fiscal years 2019 through 2023, 
22
there is authorized to be appropriated for fees under 
23
this section an amount equal to the total amount of 
24
fees assessed for such fiscal year under this section. 
25
04:32 Jun 29, 2019
H3443
93 
•HR 3443 IH
‘‘(g) COLLECTION OF UNPAID FEES.—In any case 
1
where the Secretary does not receive payment of a fee as-
2
sessed under subsection (a) within 30 calendar days after 
3
it is due, such fee shall be treated as a claim of the United 
4
States Government subject to subchapter II of chapter 37 
5
of title 31, United States Code. 
6
‘‘(h) CONSTRUCTION.—This section may not be con-
7
strued to require that the number of full-time equivalent 
8
positions in the Department of Health and Human Serv-
9
ices, for officers, employers, and advisory committees not 
10
engaged in OTC monograph drug activities, be reduced 
11
to offset the number of officers, employees, and advisory 
12
committees so engaged. 
13
‘‘SEC. 744N. REAUTHORIZATION; REPORTING REQUIRE-
14
MENTS. 
15
‘‘(a) PERFORMANCE REPORT.—Beginning with fiscal 
16
year 2019, and not later than 120 calendar days after the 
17
end of each fiscal year thereafter for which fees are col-
18
lected under this part, the Secretary shall prepare and 
19
submit to the Committee on Energy and Commerce of the 
20
House of Representatives and the Committee on Health, 
21
Education, Labor, and Pensions of the Senate a report 
22
concerning the progress of the Food and Drug Adminis-
23
tration in achieving the goals identified in the letters de-
24
scribed in section 2001(b) of the Over-the-Counter Mono-
25
04:32 Jun 29, 2019
H3443
94 
•HR 3443 IH
graph Safety, Innovation, and Reform Act of 2019 during 
1
such fiscal year and the future plans of the Food and 
2
Drug Administration for meeting such goals. 
3
‘‘(b) FISCAL REPORT.—Not later than 120 calendar 
4
days after the end of fiscal year 2019 and each subsequent 
5
fiscal year for which fees are collected under this part, 
6
the Secretary shall prepare and submit to the Committee 
7
on Energy and Commerce of the House of Representatives 
8
and the Committee on Health, Education, Labor, and 
9
Pensions of the Senate a report on the implementation 
10
of the authority for such fees during such fiscal year and 
11
the use, by the Food and Drug Administration, of the fees 
12
collected for such fiscal year. 
13
‘‘(c) PUBLIC AVAILABILITY.—The Secretary shall 
14
make the reports required under subsections (a) and (b) 
15
available to the public on the internet website of the Food 
16
and Drug Administration. 
17
‘‘(d) REAUTHORIZATION.— 
18
‘‘(1) 
CONSULTATION.—In 
developing 
rec-
19
ommendations to present to the Congress with re-
20
spect to the goals described in subsection (a), and 
21
plans for meeting the goals, for OTC monograph 
22
drug activities for the first 5 fiscal years after fiscal 
23
year 2023, and for the reauthorization of this part 
24
04:32 Jun 29, 2019
H3443
95 
•HR 3443 IH
for such fiscal years, the Secretary shall consult 
1
with— 
2
‘‘(A) the Committee on Energy and Com-
3
merce of the House of Representatives; 
4
‘‘(B) the Committee on Health, Education, 
5
Labor, and Pensions of the Senate; 
6
‘‘(C) scientific and academic experts; 
7
‘‘(D) health care professionals; 
8
‘‘(E) representatives of patient and con-
9
sumer advocacy groups; and 
10
‘‘(F) the regulated industry. 
11
‘‘(2) 
PUBLIC
REVIEW
OF
RECOMMENDA-
12
TIONS.—After negotiations with the regulated indus-
13
try, the Secretary shall— 
14
‘‘(A) present the recommendations devel-
15
oped under paragraph (1) to the congressional 
16
committees specified in such paragraph; 
17
‘‘(B) publish such recommendations in the 
18
Federal Register; 
19
‘‘(C) provide for a period of 30 calendar 
20
days for the public to provide written comments 
21
on such recommendations; 
22
‘‘(D) hold a meeting at which the public 
23
may present its views on such recommenda-
24
tions; and 
25
04:32 Jun 29, 2019
H3443
96 
•HR 3443 IH
‘‘(E) after consideration of such public 
1
views and comments, revise such recommenda-
2
tions as necessary. 
3
‘‘(3) TRANSMITTAL OF RECOMMENDATIONS.— 
4
Not later than January 15, 2023, the Secretary 
5
shall transmit to the Congress the revised rec-
6
ommendations under paragraph (2), a summary of 
7
the views and comments received under such para-
8
graph, and any changes made to the recommenda-
9
tions in response to such views and comments.’’. 
10
Æ 
04:32 Jun 29, 2019
H3443
